Page last updated: 2024-08-17

levodopa and Abnormal Movements

levodopa has been researched along with Abnormal Movements in 429 studies

Research

Studies (429)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	7 (1.63)	18.2507
2000's	152 (35.43)	29.6817
2010's	156 (36.36)	24.3611
2020's	114 (26.57)	2.80

Authors

Authors	Studies
Dahl, R	1
Fernandez, H; Hattori, N; Hauser, RA; Isaacson, SH; LeWitt, P; Li, J; Mochizuki, H; Mori, A; Nakajima, Y; Rascol, O; Ristuccia, R; Stocchi, F	1
Baik, K; Chung, SJ; Jeong, SH; Jung, JH; Lee, PH; Lee, YH; Sohn, YH; Yoo, HS	1
Bezard, E; Friedman, E; Kottmann, AH; Li, Q; Malave, L; Qin, C; Rebholz, H; Starikov, L; Uribe-Cano, S; Zuelke, DR	1
Chiu, SW; Hattori, N; Kashihara, K; Maeda, T; Nomoto, M; Saiki, H; Shimo, Y; Tsuboi, Y; Watanabe, H; Yamaguchi, T	1
Pitakpatapee, Y; Sangpeamsook, T; Srikajon, J; Srivanitchapoom, P	1
Maruyama, H; Matsumoto, Y; Nakamura, M; Tsuboi, Y	1
Caulfield, ME; Stancati, JA; Steece-Collier, K	1
Larson, D; Simuni, T	1
Harrison, DJ; Hills, R; Lane, EL; Lelos, MJ; Ramos-Varas, E; Turner, S	1
Chen, H; Feng, T; Kou, W; Liu, G; Ma, H; Su, D; Wang, D; Wang, X; Wang, Z; Zhang, Z; Zhao, J	1
Hosokawa, Y; Miyaue, N; Yabe, H	1
Batalhão, ME; Bortolanza, M; Capellari-Carnio, E; Del-Bel, EA; Pimentel, ÂV; Pinheiro, LC; Santos-Lobato, BL; Tumas, V	1
Aldred, J; Anca-Herschkovitsch, M; Bergmann, L; Bourgeois, P; Chaudhuri, KR; Cubo, E; Davis, TL; Gao, T; Iansek, R; Kovács, N; Kukreja, P; Pontieri, FE; Siddiqui, MS; Simu, M; Standaert, DG	1
Artusi, CA; Balestrino, R; Bonvegna, S; Fabbri, M; Imbalzano, G; Lopiano, L; Mancini, F; Montanaro, E; Rizzone, MG; Romagnolo, A; Zibetti, M	1
Bove, F; Calabresi, P	1
A'raaf Sirojan Kusuma, M; Akbar, M; Bintang, AK; Faridwazdi, DAN; Florentia, SW; Gustaf, A; Herawangsa, S; Raisa, N; Sativa, MO; Shodry, S; Soraya, GV; Ulhaq, ZS	1
Iwamuro, H; Nakajima, A; Odo, M; Shimo, Y; Tokugawa, J	1
Gultekin, M; Tufekcioglu, Z	1
Eskow Jaunarajs, KL; Hess, EJ; Scarduzio, M; Standaert, DG	1
Morgante, F; Pereira, EA; Pogosyan, A; Tan, H; Tinkhauser, G; Torrecillos, F; Wiest, C	1
Chen, B; Feng, ST; Hu, D; Wang, XL; Wang, ZZ; Zhang, Y	1
Girasole, AE; Kreitzer, AC; Lee, HY; Nelson, AB; Ptáček, LJ	1
Kang, HY; Kwak, N; Lee, H; Lee, MJ; Park, J; Suh, JK	1
Jing, XZ; Luo, X; Wang, XP; Yuan, XZ; Zhang, SY	1
Baayen, C; Medori, R; Meulien, D; Rascol, O; Such, P	1
Feng, T; Ma, H; Wan, Z; Wang, X; Wang, Z	1
Flisar, D; Kojović, M; Kolmančič, K; Kramberger, MG; Pirtošek, Z; Trošt, M; Zupančič, NK	1
Chen, L; Chen, Y; Cheng, O; Guo, J; Hu, S; Huang, W; Lei, L; Li, B; Li, J; Liao, W; Liu, W; Liu, Y; Liu, Z; Pan, H; Shen, Y; Sun, Q; Tan, H; Tang, B; Tang, J; Wang, C; Wang, P; Wang, Q; Wang, T; Wang, X; Wu, H; Wu, X; Xiang, Y; Xie, Y; Xu, P; Xu, Q; Xue, Z; Yan, X; Ye, M; You, Y; Yuan, K; Zhang, Z; Zhao, Y; Zhou, X; Zhou, Z; Zhu, J	1
Liparoti, M; Manzo, V; Minino, R; Sorrentino, G; Sorrentino, P; Tafuri, D; Troisi Lopez, E	1
Chaurasia, RN; Dwivedi, A; Dwivedi, N; Joshi, D; Kumar, A; Mishra, VN; Mohanty, S; Pathak, A; Singh, VK	1
Belvisi, D; Berardelli, A; Bologna, M; Conte, A; Guerra, A; Kamble, N; Pal, PK; Valls-Solè, J	1
Di Luca, DG; Fox, SH; Reyes, NGD	1
Katsuno, M; Komori, S; Nakamura, T; Suzuki, M; Tsuboi, T	1
Baróti, B; Constantin, V; Forró, T; Frigy, A; Kelemen, K; Metz, J; Mihály, I; Orbán-Kis, K; Szász, JA; Szász, RM; Szatmári, S; Török, Á	1
Anderson, S; Burchiel, KJ; Holland, MT; Jiao, J; Mantovani, A; Mitchell, KA; Safarpour, D	1
El-Masri, S; Evans, A; Malpas, CB; Walterfang, M	1
Chung, SJ; Jeong, SH; Lee, HS; Lee, PH; Sohn, YH	1
Alobaidi, A; Antonini, A; Bergmann, L; Chaudhuri, KR; Hegde, S; Odin, P; Pahwa, R; Parra, JC; Snedecor, SJ; Standaert, DG; Thakkar, S; Titova, N; Zadikoff, C	1
Barbosa, ER; Barbosa, PM; Chien, HF; Limongi, JCP; Torres, MRC	1
Hattori, N; Ishida, T; Kamei, T; Nomoto, M; Suzuki, I; Tsuboi, Y	1
Airas, L; Helin, S; Joutsa, J; Parkkola, R; Rinne, JO; Rissanen, E; Tuisku, J; Waggan, I	1
Amato, F; Artusi, CA; Calandra-Buonaura, G; Contin, M; Cortelli, P; Giannini, G; Imbalzano, G; Ledda, C; Lopiano, L; Olmo, G; Rinaldi, D; Romagnolo, A; Sambati, L; Zibetti, M	1
McCarter, SJ; Savica, R	1
Bishop, C; Bonifazi, A; Cai, NS; Campos, BC; Casadó, V; Casajuana-Martin, N; Coyle, M; Del Torrent, CL; Ferré, S; Florán, B; Galaj, E; Guitart, X; Moreno, E; Newman, AH; Pardo, L; Rea, W; Seyedian, A; Xi, ZX	1
Azar, YO; Badawi, GA; Ibrahim, SM; Zaki, HF	1
Kulisevsky, J	1
Aldred, J; Budur, K; Facheris, MF; Fisseha, N; Fung, VS; Hauser, RA; Jeong, A; Kimber, TE; Klos, K; Litvan, I; O'Neill, D; Robieson, WZ; Soileau, MJ; Spindler, MA; Standaert, DG; Talapala, S; Vaou, EO; Zheng, H	1
Isonishi, A; Kawabe, Y; Nakahara, K; Okuda, H; Tanaka, T; Tatsumi, K; Wanaka, A	1
Casado-Polanco, R; Castela, I; Costa, RM; da Silva, JA; Hernandez, LF; Marquez, R; Moratalla, R; Obeso, J; Pro, B; Redgrave, P; Rubio, YV	1
Chen, J; Ge, YL; Jin, H; Li, D; Li, K; Li, W; Liu, CF; Mao, CJ; Wang, F; Wang, PZ; Yan, JH; Yang, YP; Zhang, JR; Zhang, YC	1
Chung, SJ; Hwang, YS; Jeon, SR; Jo, S; Kim, MS; Kim, N; Lee, SH	1
Cao, L; Zhao, G; Zheng, Z	1
Chen, F; Chen, J; Fu, Y; Ge, R; Huo, Y; Ren, A; Wang, H; Wang, M	1
Cui, Y; Feng, T; Gan, Y; Jing, J; Liu, Z; Sossi, V; Stoessl, AJ; Su, D; Wang, Z; Wu, T; Zhang, Z; Zhou, J	1
Baik, K; Chung, SJ; Jeong, SH; Jung, JH; Kim, SJ; Lee, PH; Lee, YH; Na, HK; Sohn, YH; Yoo, HS	1
Almeida, RMM; Artigas, NR; Dutra, ACL; Krimberg, JS; Monticelli, BE; Pereira, GM; Rieder, CRM; Schumacher-Schuh, AF; Soares, NM	1
Buskens, E; Lunter, G; Moes, HR; Mondria, T; Portman, AT; Ten Kate, JM; van Harten, B; van Kesteren, ME; van Laar, T	1
Chiu, SW; Hattori, N; Kashihara, K; Maeda, T; Mishima, T; Nomoto, M; Saiki, H; Shimo, Y; Tsuboi, Y; Watanabe, H; Yamaguchi, T	1
Artusi, CA; Bozzali, M; Covolo, A; Imbalzano, G; Ledda, C; Lopiano, L; Martone, T; Montanaro, E; Rizzone, MG; Romagnolo, A; Zibetti, M	1
Brito, MMCM; Cavalcanti, RTO; Del-Bel, E; Pimentel, ÂV; Santos-Lobato, BL; Tumas, V	1
Alam, MR; Singh, S	1
Shih, LC; Wang, R	1
Chen, F; Chen, X; Wen, S; Zhang, Q; Zhou, C	1
Iwaki, H; Mukai, Y; Nishikawa, N; Takahashi, Y	1
Bouillot, C; Chaib, S; Depoortere, R; Levigoureux, E; Newman-Tancredi, A; Vidal, B; Zimmer, L	1
Alberquilla, S; Coll, C; Keifman, E; Moratalla, R; Murer, MG; Reig, R; Sáez, M	1
Horiba, M; Imamura, A; Kuroyanagi, G; Matsukawa, N; Murakami, H; Sakai, H; Sato, T; Takahashi, A; Ueki, Y; Usami, T	1
Amato, N; Caverzasio, S; Galati, S; Kaelin-Lang, A; Manconi, M; Staedler, C	1
Bhidayasiri, R; Bongsebandhu-Phubhakdi, S; Hopetrungraung, T; Phokaewvarangkul, O; Phowthongkum, P; Poorirerngpoom, C; Sathirapatya, T; Thanprasertsuk, S; Vongpaisarnsin, K; Wichit, P	1
Batzu, L; Bhattacharya, K; Borgohain, R; Chaudhuri, KR; Dhamija, RK; Falup-Pecurariu, C; Goyal, V; Kumar, NSS; Kumar, S; L K, P; Metta, V; Mrudula, R; Rodriguez-Blazquez, C; S, A	1
Egan, T; Kuriakose, A; Rentsch, P; Stayte, S; Vissel, B	1
Albarrán-Bravo, S; Ávalos-Fuentes, JA; Cortés, H; Erlij, D; Florán, B; Leyva-García, N; Rangel-Barajas, C; Rodriguez-Sánchez, M	1
Bonizzoni, E; Cattaneo, C; Jost, WH	1
Antonini, A; Chaudhuri, KR; Jenner, P; Leta, V	1
Bhargava, P; Blum, D; Espay, AJ; Factor, SA; Hauser, RA; Isaacson, S; Leinonen, M; Navia, B; Olanow, CW; Pahwa, R; Sciarappa, K; Shill, HA	1
Reddy, SP; Rieder, CRM; Schumacher-Schuh, AF; Socal, MP	1
Fujita, H; Haruyama, Y; Hatano, T; Hattori, N; Hirano, S; Hirata, K; Kadowaki, T; Kaji, Y; Kobashi, G; Kuwabara, S; Miyamoto, M; Okuma, Y; Sakakibara, R; Shimo, Y; Suzuki, K; Uchiyama, T; Yamamoto, T	1
Almela, P; Bautista-Hernández, V; Cuenca-Bermejo, L; de Pablos, V; Estrada, C; Fernández-Villalba, E; Herrero, MT; Laorden, ML; Yuste, JE	1
Mochizuki, H	1
Chen, N; Du, TT; Fan, SY; Guo, CJ; Han, CL; Jiang, Y; Liu, YP; Meng, FG; Shimabukuro, M; Sui, YP; Wang, KL; Wang, Q; Yuan, F; Zhang, JG	1
Anderson, S; Bankiewicz, KS; Christine, CW; Curtze, C; Hiller, A; Larson, PS; Leinonen, M; Nutt, JG; Ravina, B; Richardson, RM; Sedkov, A; Thompson, ME; Van Laar, AD	1
Chonpathompikunlert, P; Hutamekalin, P; Nagasaki, Y; Sato, Y; Tanasawet, S; Vong, LB	1
Brahimi, E; Calabresi, P; Cappelletti, G; Eusebi, P; Filidei, M; Nigro, P; Paoletti, FP; Parnetti, L; Santangelo, V; Simoni, S; Tambasco, N	1
Chung, SJ; Lee, HS; Lee, PH; Lee, YH; Sohn, YH; Yoo, HS	1
Kempster, P	1
Lang, AE; Saranza, G	1
Castela, I; Hernandez, LF	1
Cenci, MA; Eidelberg, D; Hauser, RA; Pahwa, R; Riggare, S	1
Ebersbach, G; Jost, WH; Kassubek, J; Klebe, S; Tönges, L	1
D'Souza, R; Fisher, S; Hauser, RA; Zeitlin, L	1
Andren, PE; Bezard, E; Crossman, AR; Fridjonsdottir, E; Hulme, H; Li, Q; Nilsson, A; Pioli, E	1
Altiparmak, E; Erdoğan Küçükdağli, F; Köseoğlu, HT; Öztürk, Ö; Saltoğlu, T; Sücüllü Karadağ, Y	1
Aradi, SD; Hauser, RA	1
Khojandi, A; Ramdhani, R; Vasudevan, R; Watts, J	1
Burack, MA; Ghoraani, B; Hssayeni, MD; Jimenez-Shahed, J	1
Altwal, F; Moon, C; Steiner, H; West, AR	1
Gundersen, V; Jusufovic, M; Luth, SM; Nysveen, I; Skogseid, IM	1
Dinelle, K; Felicio, AC; Fu, JF; Matarazzo, M; McKenzie, J; McKeown, MJ; Neilson, N; Sossi, V; Stoessl, AJ; Vafai, N	1
Asano, AGC; Asano, NMJ; da Silva, IIFG; De Mascena Diniz Maia, M; de Souza, PRE; Dos Santos, EUD	1
Boezwinkle, SA; Collier, TJ; Duffy, MF; Fischer, DL; Manfredsson, FP; Mercado, NM; Mueller, RL; Sandoval, IM; Sortwell, CE; Stancati, JA; Steece-Collier, K	1
Cai, J; Chen, J; Huang, S; Li, M; Li, N; Luo, F; Lv, S; Wang, J; Wang, N; Wang, Q; Wang, Y; Wen, H; Zhang, W	1
Deputy, SR; Tilton, AH	1
Bishop, C; Chambers, NE; Clark, SD; Coyle, M; Lanza, K; Saito, C; Sergio, J; Topping, B	1
Chansysouphanthong, T; Cui, G; Raza, HK; Xu, C; Zhang, W; Zu, J	1
Choi, YK; Go, J; Kim, KS; Lee, CH; Lee, IB; Park, HY; Ryu, YK	1
Dhawan, V; Eidelberg, D; Feigin, A; Fujita, K; Hellman, M; Ma, Y; Peng, S; Tang, CC	1
Bower, JH; Camerucci, E; Hajeb, M; Martin, P; Mielke, MM; Mullan, AF; Ross, OA; Savica, R; Stang, CD; Turcano, P	1
Baik, K; Chung, SJ; Hong, JM; Jung, JH; Kim, YJ; Lee, HS; Lee, PH; Lee, YH; Sohn, YH; Yoo, HS	1
Adarmes-Gómez, A; Fernández-Rodríguez, P; García-Solís, D; Grothe, MJ; Huertas, I; Jesús, S; Labrador-Espinosa, MA; Macías-García, D; Martín-Rodríguez, JF; Mir, P; Muñoz-Delgado, L	1
Blinova, NM; Derevyanko, HP; Safin, SM	1
Fujioka, S; Komorita, S; Mishima, T; Nishida, A; Okajima, M; Tsuboi, Y	1
Ahmed, H; Aziz, MAE; Bahbah, EI; Ebada, MA; Fala, SY; Ghaith, HS; Negida, A	1
Barbato, LM; Freire-Alvarez, E; Kurča, E; Liu, Y; Lopez Manzanares, L; Pekkonen, E; Sánchez-Soliño, O; Spanaki, C; Vanni, P	1
Fan, HX; Li, JJ; Li, XX; Sheng, S; Zhang, F; Zheng, CQ	1
Horne, M; Khodakarami, H; Shokouhi, N	1
Ammendolia, A; de Sire, A; Demeco, A; Marinaro, C; Moggio, L; Petraroli, A; Pino, I	1
Li, C; Liu, Y; Xu, M; Yin, Y; Zhang, X	1
Kumar, H; Pandey, S	1
Brokaw, EB; Burack, MA; Heldman, DA; Mari, ZK; Mera, TO; Pulliam, CL	1
Espay, AJ; Lang, AE	1
Borges, V; Ferraz, HB; Mata, IF; Santos-Lobato, BL; Tumas, V; Zabetian, CP	1
Wagle Shukla, A	2
Chen, SD; Du, JJ	1
Chen, J; Li, J; Liu, X; Lou, Z; Sun, Y	1
Müller, T	3
Alty, JE; Cosgrove, J; Duggan-Carter, P; Jamieson, S; Lones, MA; Naylor, RF; Smith, SL; Turner, AJ	1
Araki, A; Endo, T; Kazuta, T; Terao, S; Torii, R; Yokoi, K	1
Chang, YY; Chen, PL; Chen, YF; Lan, MY; Lin, CH	1
Carras, N; Choi, YY; Dhawan, V; Eidelberg, D; Feigin, A; Jourdain, VA; Ma, Y; Markowitz, D; Nardi, D; Nazem, A; Niethammer, M; Peng, S; Schindlbeck, KA; Tang, CC	1
Baekelandt, V; Casteels, C; Crabbé, M; Himmelreich, U; Van der Perren, A; Van Laere, K; Weerasekera, A	1
Domingos, J; Hägglund, M; Riggare, S; Stamford, JA; Sturr, J; Svenningsson, P; Unruh, KT	1
Chung, SJ; Hong, JY; Kim, JS; Lee, PH; Moon, H; Oh, JS; Sohn, YH; Ye, BS; Yoo, HS	1
Hauser, RA; Pahwa, R	1
Tomiyama, M	1
Chen, J; Huang, JY; Jin, H; Liu, CF; Mao, CJ; Wang, F; Xu, LL; Yang, Y; Yang, YP; Zhang, HJ; Zhang, JR; Zhong, CK	1
Brys, I; Halje, P; Newman-Tancredi, A; Petersson, P; Scheffer-Teixeira, R; Varney, M	1
Hagell, P; Horne, M; Iwarsson, S; Nilsson, MH; Odin, P; Rosqvist, K	1
Asano, AGC; Asano, NMJ; Crovella, S; da Silva, RC; de Lima, GDC; de Souza, PRE; Dos Anjos, RSG; Dos Santos, EUD; Sampaio, TF	1
Ahanonu, B; Ding, JB; Ehlers, MD; Grewe, BF; Kim, TH; Li, JZ; Marshall, JD; Parker, JG; Schnitzer, MJ; Wu, YW; Zhang, Y	1
Antonini, A; Nitu, B	1
Dinh, P	1
Jenner, P	1
Antonini, A; Bergmann, L; Chaudhuri, KR; Poewe, W	1
Hamel, W; Hariz, M; Köppen, JA; Krack, P; Moll, CKE; Müller, D	1
Belforte, JE; Escande, MV; Gershanik, OS; Gomez, G; Moratalla, R; Murer, MG; Rela, L; Suarez, LM; Taravini, IRE	1
Corvol, JC; Mariani, LL	1
Urs, NM	1
Hara, K; Hattori, M; Kajita, Y; Katsuno, M; Kawabata, K; Maesawa, S; Nakatsubo, D; Ohdake, R; Sato, M; Sobue, G; Tanaka, Y; Tsuboi, T; Watanabe, H	1
Dong, X; Nao, J; Zheng, D	1
Bezard, E; Fernagut, PO; Li, Q	1
Buhmann, C; Jost, WH; Kassubek, J; Lingor, P; Schrag, A; Schwarz, J; Tönges, L	1
Farzanehfar, P; Horne, M; Khodakarami, H	1
McFarthing, K; Prakash, N; Simuni, T	1
Gupta, S; Hsu, A; Mao, Z; Modi, NB	1
Ossig, C; Reichmann, H	1
Morais, BA; Ragazzo, PC; Silva, DJ; Souza, JT; Vilela-Filho, O	1
Breger, LS; Lane, EL	1
Arfon, S; Drago, J; Evans, A; Griffiths, RI; Horne, MK; Johnson, W; Kempster, P; Kotschet, K; Raghav, S; Xu, ZM	1
Levin, OS; Liashchenko, EA; Skripkina, NA	1
Jeon, BS; Kim, JM; Lee, JY; Yang, HJ	1
Hurley, MJ; Jackson, MJ; Jenner, P; Rose, S; Smith, LA	1
Amarell, M; Barbe, MT; Bloem, BR; Fink, GR; Florin, E; Quatuor, EL; Schönau, E; Snijders, AH; Timmermann, L	1
Hisanaga, R; Nakamura, M; Nomoto, S; Sato, T	1
Bezard, E; De Deurwaerdere, P; Li, Q; Marti, M; Meissner, WG; Morari, M; Morgenstern, R; Porras, G; Sohr, R	1
Fedorova, NV; Kulua, TK	1
Carta, M; Collu, M; Fidalgo, C; Gardoni, F; Morelli, M; Stancampiano, R; Tronci, E; Zianni, E	1
Evans, AH; Griffiths, RI; Horne, M; Kettlewell, J; Kotschet, K; McGregor, S	1
Cenci, MA	1
Jenner, P; Kanda, T; Kawai-Uchida, M; Mori, A; Tashiro, T; Uchida, S	1
Chakrabarty, K; Drucker-Colín, R; Garcia-Montes, JR; Herrero, MT; Heumann, R; Moratalla, R; Morelli, M; Simola, N	1
Hattori, N	1
Di Paolo, T; Fox, S; Gasparini, F; Gomez-Mancilla, B; Kenney, C; Rascol, O	1
Iravani, M; Jackson, M; Jenner, P; McCreary, AC; Papathanou, M; Rose, S; Stockwell, K; Strang, I; Zeng, BY	1
Burack, MA; Giuffrida, JP; Heldman, DA; Mera, TO; Pulliam, CL	1
Liu, Z; Wang, Q; Xie, C; Zhang, S	1
Chen, Z; Dragan, EM; Ondo, WG	1
Boroojerdi, B; Ghys, L; Giladi, N; Jankovic, J; Surmann, E	1
Che, JY; Gan, J; Liu, ZG; Song, L; Wang, WW; Xie, CL; Yuan, ML; Yuan, WE; Zhang, SF	1
Björklund, A; Brooks, DJ; Hart, T; Loane, C; Odin, P; Piccini, P; Politis, M; Smith, R; Wu, K	1
Cannas, A; Marrosu, F; Orofino, G; Solla, P	1
Akram, H; Angeli, A; Foltynie, T; Hariz, M; Limousin, P; Zacharia, A; Zrinzo, L	1
Bass, CE; Bezard, E; Bido, S; Caron, MG; Daigle, TL; Gainetdinov, RR; Peterson, SM; Urs, NM	1
Antonelli, F; Buongiorno, M; Calopa, M; Cámara, A; Campolongo, A; de Fabregues-Nebot, O; Hernandez-Vara, J; Kulisevsky, J; Martí, MJ; Pascual-Sedano, B; Puente, V; Tolosa, E; Valldeoriola, F	1
Ahmed, MR; Bychkov, E; Gurevich, EV; Gurevich, VV; Li, L	1
Bizzarri, BM; Botta, G; Rotelli, L; Saladino, R; Tortolini, S	1
Antonini, A; Chaudhuri, KR; Fox, K; Fox, T; Honig, H; Martinez-Martin, P; Odin, P; Timpka, J	1
Bonizzoni, E; Cattaneo, C; Ferla, RL; Sardina, M	1
Aquino, CC; Beaulieu-Boire, I; Fox, SH; Lui, JP; Mestre, TA; Phielipp, N; Poon, YY; So, J	1
Alves, G; Bjornestad, A; Forsaa, EB; Larsen, JP; Pedersen, KF; Tysnes, OB	1
Bereczki, D; Nagy, H; Takáts, A; Toth, A; Wacha, J	1
Chang, FC; Fung, VS; Griffith, JM; Ha, AD; Kim, SD; Kwan, V; Mahant, N; Tsui, D; van der Poorten, D; Wolfe, N	1
Alvarsson, A; Greengard, P; Kaplitt, MG; Marongiu, R; Schintu, N; Svenningsson, P; Zhang, X	1
Bishop, C; Conti, MM; Eissa, S; Goldenberg, AA; Kuberka, A; Lindenbach, D; Mohamed, M	1
Alcaine, S; Annicchiarico, R; Bayes, A; Browne, P; Cabestany, J; Costa, A; Counihan, TJ; Laighin, GÓ; Lewy, H; Mestre, B; Moreno-Aróstegui, JM; Pérez-López, C; Quinlan, LR; Quispe, P; Rodríguez-Martín, D; Rodríguez-Molinero, A; Samà, A; Sweeney, D	1
Bardinet, E; Burkhard, P; Chabardes, S; Combescure, C; Fleury, V; Gere, J; Krack, P; Krainik, A; Momjian, S; Pollak, P; Romito, L; Tommasi, G; Yelnik, J	1
Cirnaru, MD; Di Luca, M; Gardoni, F; Mellone, M; Perez-Carrion, M; Piccoli, G; Stanic, J; Zianni, E	1
Jog, MS; Kumar, N; Rizek, P	1
Avolio, C; De Francesco, V; Lalla, A; Martino, T; Melchionda, D; Specchio, LM; Tonti, P	1
Chen, G; He, Y; Liu, S; Liu, Z; Wei, N; You, J; Zhao, XE; Zheng, L; Zhu, S	1
Bianchi, ML; Bono, G; Cantello, R; Comi, C; Cosentino, M; Ferrari, M; Magistrelli, L; Marino, F; Riboldazzi, G	1
Bordia, T; Perez, XA; Quik, M; Zhang, D	1
Castela, I; F Hernández, L; Moratalla, R; Obeso, JA; Ruiz-DeDiego, I	1
Bimpisidis, Z; Cenci, MA; Lundblad, C; Maslava, N; Öberg, CM	1
DeLong, MR; Liang, L; Papa, SM	1
Collier, TJ; Freeman, TB; McGuire, SO; Meredith, G; Soderstrom, KE; Sortwell, CE; Steece-Collier, K; Wu, Q	1
Brundin, P; Cenci, MA; Lane, EL; Soulet, D; Vercammen, L	1
Belkhir, S; Di Paolo, T; Dridi, M; Grégoire, L; Meltzer, LT; Morissette, M; Ouattara, B; Samadi, P	1
Jin, GZ; Mo, J; Sun, PH; Yu, LP; Zhang, H; Zhen, X	1
Evans, AH; Farrell, MJ; Gibson, SJ; Helme, RD; Lang, AE; Lim, SY	1
Gunzler, SA; Hogarth, P; Jamerson, B; Kirchhoff, T; Krams, M; Landen, JW; Menniti, FS; Nutt, JG; Weaver, JL	1
Garamendi, I; Gómez, JC; Lezcano, E; Rouco, I; Tijero, B; Velasco, F; Zarranz, JJ	1
Fox, SH; Lang, AE	1
Albanese, A; Del Sorbo, F	1
Aasly, JO; Beiske, AG; Bekkelund, SI; Dietrichs, E; Larsen, JP; Tysnes, OB; Vilming, ST	1
Wang, J; Ye, Q; Yuan, CG; Yuan, CX; Zhang, Y	1
Armand, S; Burkhard, PR; Landis, T; Sztajzel, R	1
Babina, LA; Batysheva, TT; Boiko, AN; Khozova, AA; Kostenko, EV; Malykhina, EA; Minaeva, NG; Shikhkerimov, RK; Vdovichenko, TV; Zaitsev, KA; Zhuravleva, EY	1
Freeman, T; Godbold, J; Goetz, CG; Gracies, JM; Kordower, JH; Obeso, JA; Olanow, CW; Stoessl, AJ	1
Antonelli, T; Cassano, T; Cuomo, V; Dipasquale, P; Ferraro, L; Gaetani, S; Giuffrida, A; Laconca, L; Macheda, T; Morgese, MG	1
Ayres-Basto, M; Gago, MF; Linhares, P; Rosas, MJ; Sousa, G; Vaz, R	1
Castagnoli, N; Chen, JF; Petzer, JP; Schwarzschild, MA; Van der Schyf, CJ	1
Alcacer, C; Cacciatore, S; Fisone, G; Girault, JA; Greengard, P; Heiman, M; Hervé, D; Santini, E; Valjent, E	1
Ben-Shlomo, Y; Morris, HR; Wickremaratchi, MM	1
Alvarez, L; Alvarez, M; Carballo, M; Casabona, E; DeLong, MR; Fernández, R; García, I; Guridi, J; Juncos, JL; López, G; Macias, R; Maragoto, C; Obeso, JA; Pavón, N; Pedroso, I; Rodríguez, R; Rodríguez-Oroz, MC; Salazar, S; Teijeiro, J	1
Lang, AE	1
Poewe, W	1
Brundin, P; Cenci, MA; Lane, EL	1
Bachmann, CG; Brunner, E; Trenkwalder, C; Zapf, A	1
Fernández-Alvarez, E	1
Delvaux, V; Garraux, G; Moonen, G	1
Chen, W; Liu, ZG; Lu, LX; Qi, C; Wu, JY; Zhou, MZ	1
Araki, H; Inuzuka, T; Kato, T; Moriwaki, H; Murase, M; Nagaki, M; Nishida, H; Tanaka, Y	1
Tarsy, D	1
Ikeda, K; Kurokawa, T; Mochizuki, H; Nakao, K; Yoshikawa, S; Yuzawa, N	1
Aguilar, E; Cortés, R; Marin, C; Mengod, G; Obeso, JA	1
Letro, GH; Quagliato, EM; Viana, MA	1
Chelaru, MI; Duval, C; Jog, M	1
Alty, JE; Clissold, BG; Kempster, PA; McColl, CD; Reardon, KA; Shiff, M	1
Annesi, G; Arabia, G; Barone, P; Cozzolino, A; De Mari, M; Epifanio, A; Gallerini, S; Lamberti, P; Marconi, R; Morgante, L; Nicoletti, A; Nicoletti, G; Pugliese, P; Quattrone, A; Torchia, G; Zappia, M	1
Amar, K; Eggert, K; Kuoppamäki, M; Leinonen, M; Luotonen, L; Nissinen, H; Oertel, W; Skogar, O	1
Litvinenko, IV; Mogil'naya, VI; Odinak, MM; Perstnev, SV	1
Askmark, H; Karlsson, E; Lundberg, M; Nyholm, D	1
Antonini, A; Chaudhuri, KR; Martinez-Martin, P; Odin, P	1
Collier, TJ; Levine, ND; O'Malley, JA; Soderstrom, KE; Sortwell, CE; Steece-Collier, K	1
Jackson, MJ; Jenner, P; Olanow, CW; Rose, S; Tayarani-Binazir, KA	1
Björklund, T; Carlsson, T; Carta, M; Cederfjäll, EA; Kirik, D	1
Björklund, A; Carlsson, T; Carta, M; Kirik, D; Muñoz, A	1
Cardinali, DP; Merello, M; Perez Lloret, S; Rossi, M	1
Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E	1
Bagetta, V; Calabresi, P; Ghiglieri, V; Picconi, B; Sgobio, C	1
Ahmed, MR; Aubert, I; Berthet, A; Bezard, E; Bioulac, BH; Bloch, B; Bychkov, E; Carl, YT; Doudnikoff, E; Dovero, S; Gurevich, EV; Gurevich, VV; Kook, S; Li, Q; Porras, G	1
Marconi, S; Stocchi, F	1
Eggert, K; Eichhorn, T; Oertel, WH; Ries, V; Selzer, R	1
Cao, X; Mochizuki, H; Mouradian, MM; Papa, SM; Uthayathas, S; Watts, RL; Yasuda, T	1
Mink, JW; Zinner, SH	1
Bachmann, CG; Linazasoro, G; Sharma, JC	1
Clarke, CE; Deane, K; Furmston, A; Gray, R; Handley, K; Ives, N; Stowe, R; Wheatley, K	1
Classen, J; Hallett, M; Morgante, F; Quartarone, A; Rosenkranz, K	1
Bhatia, KP; Cantello, R; Carecchio, M; Collini, A; Comi, C; Monaco, F	1
Bezard, E; Dovero, S; Fisone, G; Li, Q; Santini, E; Savasta, M; Sgambato-Faure, V	1
Espay, AJ	1
Lane, EL; Smith, GA	1
Berthet, A; Bézard, E	1
Bernardos, VS; Del Pozo, SV; López, IC; Ruiz, PJ	1
Haahr, A; Hall, EO; Kirkevold, M; Ostergaard, K	1
Kishore, A; Krishnan, S; Panikar, D; Rao, R; Sarma, G; Sarma, S; Sivasanakaran, MP	1
Gray, WK; Howells, AR; Walker, RW	1
Atula, S; Heikkinen, E; Jaakkola, MR; Keränen, T; Martikainen, K; Pekka, J; Pekkonen, E; Reijo, M; Sotaniemi, K	1
Britt, JP; Ding, Y; Kang, UJ; Lim, SA; McGehee, DS; Won, L	1
Fujimoto, K; Hattori, N; Kondo, T; Murata, M	1
Danoudis, M; Iansek, R	1
Albanese, A; Dollenz, C; Elia, AE; Soliveri, P	1
Konitsiotis, S; Maranis, S; Tsouli, S	1
Jakobi, JM; Jones, GR; Powell, C; Roland, KP	1
Fox, S; Meissner, WG; Prashanth, LK	1
Aristieta, A; Cenci, MA; Miguelez, C; Ugedo, L	1
Carlsson, T; Döbrössy, M; García, J; Nikkhah, G; Winkler, C	2
Andersson, M; Bergquist, J; Fälth, M; Hanrieder, J; Ljungdahl, A	1
Benabid, AL	1
de Fabregues, O; Marin, C; Rodriguez-Oroz, MC	1
Armentero, MT; Blandini, F	1
Fotiadis, DI; Konitsiotis, S; Tsipouras, MG; Tzallas, AT	1
Adkins, CE; Cenci, MA; Lockman, PR; Lundblad, C; Ohlin, KE; Sebastianutto, I	1
Abuirmeileh, A; Bloom, SR; Harkavyi, A; Lever, R; Rampersaud, N; Tadross, JA; Whitton, PS	1
Li, Y; Liu, W; Sha, C; Sun, K; Wang, A; Wang, L	1
Aman, A; Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB	1
Alegre, M; Alonso-Frech, F; Artieda, J; Guridi, J; López-Azcárate, J; Obeso, JA; Rodríguez-Oroz, MC; Valencia, M	1
Quintana, A; Savasta, M; Sgambato-Faure, V	1
Khan, TS	1
Al Hadithy, AF; Alifirova, VM; Brouwers, JR; Fedorenko, OY; Freidin, MB; Govorin, NV; Ivanova, SA; Loonen, AJ; Pechlivanoglou, P; Rudikov, EV; Semke, AV; Sorokina, VA; Wilffert, B; Zhukova, IA	1
Agid, Y; Cornu, P; Deuschl, G; Knudsen, K; Pinsker, MO; Rau, J; Schade-Brittinger, C; Schüpbach, M	1
Berger, SP; Giuffrida, A; Johnson, SW; Macheda, T; Martinez, AA; Meshul, CK; Paquette, MA	1
Liu, ZG; Song, L; Wei, JL; Wu, N; Yang, XX	1
Jenner, P; McCreary, AC; Papathanou, M; Rose, S; van der Laan, R	1
Bezard, E	2
Lane, EL; Winkler, C	1
Bloem, BR; Koopmans, RT; Munneke, M; Poels, PJ; Tissingh, G; Weerkamp, NJ; Zuidema, SU	1
Aron Badin, R; Auguet, M; Bertrand, A; Boulet, S; Brouillet, E; Chabrier, PE; Dollé, F; Gaillard, MC; Guillermier, M; Hantraye, P; Jan, C; Malgorn, C; Savasta, M; Spinnewyn, B; Van Camp, N	1
Carter, JH; Lea, ES; Nutt, JG; Sexton, GJ	1
Di Monte, DA; Langston, JW; Police, S; Quik, M	1
Levenson, D	1
Olanow, CW; Ruggieri, S; Stocchi, F; Vacca, L	2
Montgomery, EB	1
Deuschl, G; Fietzek, U; Kopper, F; Krack, P; Mehdorn, HM; Müller, D; Poepping, M; Schrader, B; Wenzelburger, R; Zhang, BR	1
Liou, HH; Liu, HM; Su, PC; Tseng, HM; Yen, RF	2
Bonhomme, C; Braceras, R; Chezaubernard, C; Del Signore, S; Hansard, MJ; Jackson, MJ; Jenner, P; Rose, S; Smith, LA; Tel, BC	1
Ohye, C; Shibazaki, T	1
Cavalcante, JE; Ferraz, FP; Santos, LF; Silva, DJ; Silva, LG; Sousa, JT; Souza, HA; Vilela Filho, O	1
Brown, P; Harnack, D; Kupsch, A; Magill, PJ; Meissner, W; Sharott, A	1
Feldon, J; Mintz, M; Mura, A	1
Hamada, I; Hasegawa, N; Okiyama, R; Takahashi, H; Taniguchi, M; Yokochi, F	1
MacMahon, D; Sharma, J; Stewart, D	1
Baas, H; Fuchs, G; Gemende, I; Hueber, R; Lachenmayer, L; Schneider, E; Schoenberger, B; Werner, M	1
Arabia, G; Bagalà, A; Bastone, L; Bosco, D; Caracciolo, M; Crescibene, L; Quattrone, A; Scornaienghi, M; Zappia, M	1
Blanchet, PJ	1
Martin, WR; Wieler, M	1
Calandrella, D; Martignoni, E; Riboldazzi, G; Riva, N	1
Stocchi, F	1
Asbrock, N; Ferrer, B; Giuffrida, A; Kathuria, S; Piomelli, D	1
Deuschl, G; Gölge, M; Hamel, W; Illert, M; Kopper, F; Krack, P; Kuhtz-Buschbeck, J; Weinert, D; Wenzelburger, R; Witt, K; Zhang, BR	1
Liu, HM; Su, PC; Tseng, HM	1
Albani, F; Baruzzi, A; Contin, M; Martinelli, P; Riva, R; Scaglione, C	1
Bonastre, M; Bové, J; Jiménez, A; Marin, C; Tolosa, E	1
Nutt, JG	3
Kang, UJ; Kim, YS; Lee, EA; Lee, WY	1
Armellino, K; Di Iorio, A; Iacono, D; Luciano, AL; Onofrj, M; Thomas, A	1
Blandini, F	1
Brocco, M; Brotchie, J; Crossman, A; Di Cara, B; Gobert, A; Hill, M; Jackson, M; Jenner, P; Joyce, JN; McGuire, S; Millan, MJ; Peglion, JL; Smith, L	1
Bezard, E; Brotchie, JM; Crossman, AR; Grimée, R; Hill, MP; Klitgaard, H; Michel, A; Ravenscroft, P	1
Bédard, PJ; Calon, F; Di Paolo, T; Dridi, M; Hornykiewicz, O; Rajput, AH	1
Cenci, MA; Lundblad, M; Poewe, W; Stefanova, N; Tison, F; Wenning, GK	1
Brachet, P; Damier, P; Paillé, V	1
Carter, JH; Nutt, JG; Sexton, GJ	1
Hamani, C; Lozano, A; Toda, H	1
Follett, KA	1
Agnati, LF; Ferré, S; Franco, R; Fuxe, K; Hockemeyer, J; Leo, G; Lluis, C; Martínez, E; Vergoni, AV	1
Guridi, J; Obeso, JA; Palmero, MR; Rodriguez-Oroz, MC; Zamarbide, I	1
Bhatia, K; Evans, A; Hoffman, M; Hughes, A; Katzenschlager, R; Lees, AJ; Manson, AJ; Quinn, N; Swinn, L; Watt, H	1
Bain, PG; Carroll, CB; Fox, P; Hobart, J; Joint, C; Liu, X; Parkin, SG; Teare, L; Wright, D; Wroath, C; Zajicek, JP	1
Jung, SK	1
Evans, A; Katzenschlager, R; Lees, AJ; Manson, A; Patsalos, PN; Ratnaraj, N; Timmermann, L; Van der Giessen, R; Watt, H	1
Baba, M; Ichinohe, N; Kimura, T; Matsunaga, M; Mori, F; Tomiyama, M; Wakabayashi, K	1
Cheetham, SC; Jenner, P; Lane, EL	1
Brotchie, JM; Collingridge, GL; Garner, CC; Johnston, TH; Nash, JE	1
Brus, R; Kostrzewa, JP; Kostrzewa, RA; Kostrzewa, RM; Nowak, P	1
Chen, L; Di Monte, DA; Langston, JW; Quik, M; Togasaki, DM	1
Lim, E	1
Apaydin, H; Kiliç, E; Ozekmekçi, S	1
Morelli, M; Pinna, A; Simola, N; Wardas, J	1
Bédard, PJ; Di Paolo, T; Grégoire, L; Hadj Tahar, A; Rouillard, C; Samadi, P	1
Meixensberger, J; Preul, C; Schwarz, J; Strecker, K; Tittgemeyer, M; Winkler, D	1
Benabid, AL; Fraix, V; Gentil, M; Krack, P; Pinto, S; Pollak, P; Sauleau, P	1
Farrugia, R; Felice, A; Neville, BG; Parascandalo, R	1
Martín, AB; Mendialdua, A; Moratalla, R; Pavón, N	1
Arnold, G; Bergamasco, B; Dujardin, M; Frewer, P; Gimenez-Roldan, S; Grosset, DG; Hundemer, HP; Leenders, KL; Lledó, A; Oertel, WH; Sampaio, C; Schwarz, J; Wolters, E; Wood, A	1
Björklund, A; Carlsson, T; Cenci, MA; Kirik, D; Lundblad, M; Winkler, C	1
Aa Sunde, N; Østergaard, K	1
Berdeaux, G; Clarke, CE; Deschaseaux-Voinet, C; Khoshnood, B; Péchevis, M; Vieregge, P; Ziegler, M	1
Antico, J; Merello, M; Obeso, JA; Perez-Lloret, S	1
Bishop, C; Rice, KC; Taylor, JL; Ullrich, T; Walker, PD	1
Bédard, PJ; Di Paolo, T; Grégoire, L; Lévesque, D; Rouillard, C; Samadi, P	1
Aguilar, E; Marin, C; Obeso, JA	1
Aguilar, E; Bové, J; Cortés, R; Marin, C; Mengod, G; Serrats, J	1
Bezard, E; Bioulac, B; Boraud, T; Gross, CE; Harnack, D; Klitgaard, H; Kupsch, A; Meissner, W; Morgenstern, R; Ravenscroft, P; Reese, R	1
Cenci, MA; Danysz, W; Dekundy, A; Pietraszek, M; Schaefer, D	1
Soghomonian, JJ	1
Brodsky, MA; Hogarth, P; Nutt, JG	1
Armenise, E; de Mari, M; Defazio, G; Dell'Aquila, C; Diroma, C; Fraddosio, A; Iliceto, G; Lamberti, P; Lamberti, SV; Livrea, P; Zoccolella, S	1
Deuschl, G; Fisman, DN; Herzog, J; Kleiner-Fisman, G; Lang, AE; Lyons, KE; Pahwa, R; Tamma, F	1
Müller, T; Russ, H	1
Chung, SJ; Hong, SH; Jeon, SR; Kim, SR; Lee, MC	1
Chung, SJ; Jeon, SR; Kim, SR; Lee, MC; Sung, YH	1
Eusebio, A; Gubellini, P; Kerkerian-Le Goff, L; Melon, C; Oueslati, A; Salin, P	1
Nyholm, D	1
Audiffren, M; Ballanger, B; Desmurget, M; Gil, R	1
Hauser, RA; McDermott, MP; Messing, S	1
Agid, Y; Blau, N; Remy, P; Ribeiro, MJ; Saudubray, JM; Sedel, F	1
Waldvogel, D	1
Brachet, P; Damier, P; Henry, V; Lescaudron, L; Paillé, V	1
Amri, M; Gubellini, P; Kachidian, P; Kerkerian-Le Goff, L; Melon, C; Oueslati, A; Salin, P; Sgambato-Faure, V	1
Haeger, DA; Hock, K; Müller, T; Russ, H; Woitalla, D	1
Ellrichmann, G; Müller, T; Russ, H	1
Bishop, C; Dupre, KB; Eskow, KL; Negron, G	1
Antonini, A; Canesi, M; Dal Fante, M; Isaias, IU; Lopiano, L; Mancini, F; Manfredi, L; Pezzoli, G; Zibetti, M	1
Burkhard, PR; Grötzsch, H; Sztajzel, R	1
Erikh, I; Schlesinger, I; Yarnitsky, D	1
Marinus, J; van Hilten, JJ; van Rooden, SM; Verbaan, D; Visser, M	1
Goto, S; Hamasaki, T; Kuratsu, JI; Yamada, K	1
Muthane, U; Ragothaman, M	1
Adena, MA; Halliday, GM; Hely, MA; Morris, JG; Reid, WG	1
Bezard, E; Guo, JT; Hengerer, B; Ittrich, C; Li, Q; Nadjar, A; Schuster, S	1
Chan, DK; Cordato, DJ; O'Rourke, F	1
Brotchie, JM; Crossman, AR; Fox, SH; Henry, B; Peggs, D	1
Giduz, T; Pact, V	1
Aguglia, U; Andreoli, V; Annesi, G; Branca, D; Cittadella, R; Civitelli, D; Gambardella, A; Montesanti, R; Nicoletti, G; Oliveri, RL; Pasqua, AA; Quattrone, A; Spadafora, P; Zappia, M	1
Desimone, R; Fiorani, M; Oldfield, EH; Papa, SM	1
Gottwald, MD	1
Scheife, RT	1
Andersson, M; Cenci, MA; Hilbertson, A	1
Cáceres, M; Costello, G; Herrera, EJ; Suárez, JC; Suárez, M; Viano, JC	1
Clarke, CE; Deane, KH	4
Baas, H; Engelhardt, M; Harder, S; Reuter, I	1
Alvarez, E; Alvarez, L; DeLong, MR; Guridi, J; Hetherington, H; Juncos, J; Lopez, G; Macias, R; Maragoto, C; Obeso, JA; Ochoa, L; Pavon, N; Rodriguez-Oroz, MC; Teijeiro, J; Torres, A	1
Linazasoro, G	1
de Luis, P; del Real, MA; Gudín, M; Hernández, A; Ibáñez, R; Vaamonde, J	1
Ağan, K; Aktan, S; Gunal, DI	1
Brotchie, JM; Crossman, AR; Fox, SH; Henry, B	1
Chassain, C; Durif, F; Eschalier, A	1
Ohye, C	1
Blatt, JL; Blond, S; Bourriez, JL; Defebvre, L; Destée, A; Duhamel, A; Guieu, JD; Kemoun, G; Krystkowiak, P; Perina, M	1
Müngersdorf, M; Reichmann, H; Sommer, M; Sommer, U	1
Arai, A; Baba, M; Kannari, K; Kurahashi, K; Maeda, T; Matsunaga, M; Suda, T; Tomiyama, M	1

Reviews

102 review(s) available for levodopa and Abnormal Movements

Article	Year
Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials. Journal of Parkinson's disease, 2021, Volume: 11, Issue:4 Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Double-Blind Method; Dyskinesias; Humans; Levodopa; Parkinson Disease; Purinergic P1 Receptor Antagonists; Purines; Randomized Controlled Trials as Topic; Receptor, Adenosine A2A; Treatment Outcome	2021
Rhabdomyolysis Associated with Severe Levodopa-Induced Dyskinesia in Parkinson's Disease: A Report of Two Cases and Literature Review. Tremor and other hyperkinetic movements (New York, N.Y.), 2021, Volume: 11 Topics: Antiparkinson Agents; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Rhabdomyolysis	2021
New dopaminergic therapies for PD motor complications. Neuropharmacology, 2022, 02-15, Volume: 204 Topics: Alanine; Antiparkinson Agents; Apomorphine; Benzylamines; Delayed-Action Preparations; Disease Progression; Dopamine Agents; Dopamine Agonists; Drug Compounding; Drug Delivery Systems; Dyskinesias; Humans; Levodopa; Oxadiazoles; Parkinson Disease	2022
Plasticity, genetics, and epigenetics in l-dopa-induced dyskinesias. Handbook of clinical neurology, 2022, Volume: 184 Topics: Antiparkinson Agents; Corpus Striatum; Dyskinesias; Epigenesis, Genetic; Humans; Levodopa; Parkinson Disease	2022
Polymorphisms of the dopamine metabolic and signaling pathways are associated with susceptibility to motor levodopa-induced complications (MLIC) in Parkinson's disease: a systematic review and meta-analysis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022, Volume: 43, Issue:6 Topics: Brain-Derived Neurotrophic Factor; Dopamine; Dyskinesias; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease; Signal Transduction	2022
Striatal Synaptic Dysfunction in Dystonia and Levodopa-Induced Dyskinesia. Neurobiology of disease, 2022, Volume: 166 Topics: Antiparkinson Agents; Corpus Striatum; Dyskinesias; Dystonia; Dystonic Disorders; Humans; Levodopa	2022
Finely-tuned gamma oscillations: Spectral characteristics and links to dyskinesia. Experimental neurology, 2022, Volume: 351 Topics: Deep Brain Stimulation; Dyskinesias; Humans; Levodopa	2022
Efficacy and safety of istradefylline for Parkinson's disease: A systematic review and meta-analysis. Neuroscience letters, 2022, 03-23, Volume: 774 Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Parkinson Disease; Purines; Treatment Outcome	2022
Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis. Journal of Parkinson's disease, 2022, Volume: 12, Issue:3 Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Dyskinesias; Humans; Levodopa; Oxadiazoles; Parkinson Disease; Randomized Controlled Trials as Topic	2022
An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson's Disease. Current neuropharmacology, 2023, Volume: 21, Issue:8 Topics: Antiparkinson Agents; Dopamine; Dyskinesias; Humans; Levodopa; Parkinson Disease; Serotonin; Zonisamide	2023
Association of Catechol-O-Methyltransferase Gene rs4680 Polymorphism and Levodopa Induced Dyskinesia in Parkinson's Disease: A Meta-Analysis and Systematic Review. Journal of geriatric psychiatry and neurology, 2023, Volume: 36, Issue:2 Topics: Catechol O-Methyltransferase; Dyskinesias; Genetic Predisposition to Disease; Genotype; Humans; Levodopa; Parkinson Disease; Polymorphism, Single Nucleotide	2023
Dystonia, chorea, hemiballismus and other dyskinesias. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2022, Volume: 140 Topics: Chorea; Dyskinesias; Dystonia; Dystonic Disorders; Humans; Levodopa	2022
Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease. Drugs, 2022, Volume: 82, Issue:10 Topics: Antiparkinson Agents; Drugs, Investigational; Dyskinesias; Humans; Levodopa; Parkinson Disease; Quality of Life	2022
Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up. Journal of Parkinson's disease, 2022, Volume: 12, Issue:7 Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Follow-Up Studies; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life; Sleep	2022
How I treat Parkinson's disease. Arquivos de neuro-psiquiatria, 2022, Volume: 80, Issue:5 Suppl 1 Topics: Antiparkinson Agents; Disease Progression; Dyskinesias; Humans; Levodopa; Parkinson Disease; Quality of Life	2022
Autopallidotomy: From Colloquial Term to Scientific Theory. Journal of Parkinson's disease, 2022, Volume: 12, Issue:7 Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dyskinesias; Globus Pallidus; Levodopa; Parkinson Disease; Parkinsonian Disorders	2022
Pharmacological management of Parkinson's disease motor symptoms: update and recommendations from an expert. Revista de neurologia, 2022, 10-31, Volume: 75, Issue:s04 Topics: Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Middle Aged; Parkinson Disease; Quality of Life	2022
Neuromodulation in Parkinson's disease targeting opioid and cannabinoid receptors, understanding the role of NLRP3 pathway: a novel therapeutic approach. Inflammopharmacology, 2023, Volume: 31, Issue:4 Topics: Analgesics, Opioid; Dyskinesias; Humans; Levodopa; NLR Family, Pyrin Domain-Containing 3 Protein; Parkinson Disease; Quality of Life; Receptors, Cannabinoid	2023
Parkinson's disease - current treatment. Current opinion in neurology, 2023, 08-01, Volume: 36, Issue:4 Topics: Antiparkinson Agents; Disease Progression; Dyskinesias; Humans; Levodopa; Parkinson Disease	2023
Dopamine agonists versus levodopa monotherapy in early Parkinson's disease for the potential risks of motor complications: A network meta-analysis. European journal of pharmacology, 2023, Sep-05, Volume: 954 Topics: Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Network Meta-Analysis; Parkinson Disease; Pergolide; Pramipexole	2023
Levodopa-Carbidopa Intestinal Gel Injection for Patient with Severe Parkinson's Disease Followed by Total Hip Arthroplasty: A Case Report and Literature Review. Orthopaedic surgery, 2023, Volume: 15, Issue:11 Topics: Antiparkinson Agents; Arthroplasty, Replacement, Hip; Carbidopa; Drug Combinations; Dyskinesias; Female; Gels; Humans; Levodopa; Middle Aged; Parkinson Disease	2023
Can therapeutic strategies prevent and manage dyskinesia in Parkinson's disease? An update. Expert opinion on drug safety, 2019, Volume: 18, Issue:12 Topics: Animals; Antiparkinson Agents; Deep Brain Stimulation; Drug Delivery Systems; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Parkinson Disease	2019
Levodopa challenge test: indications, protocol, and guide. Journal of neurology, 2021, Volume: 268, Issue:9 Topics: Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Parkinson Disease	2021
Shedding light on dyskinesias. The European journal of neuroscience, 2021, Volume: 53, Issue:7 Topics: Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Humans; Levodopa	2021
Medical Management and Prevention of Motor Complications in Parkinson's Disease. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2020, Volume: 17, Issue:4 Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Disease Management; Dyskinesias; Humans; Levodopa; Parkinson Disease	2020
Treatment of Disorders of Tone and Other Considerations in Pediatric Movement Disorders. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2020, Volume: 17, Issue:4 Topics: Autoimmune Diseases; Cerebral Palsy; Child; Dyskinesias; Humans; Levodopa; Metabolism, Inborn Errors; Movement Disorders; Muscle Tonus; Neurodegenerative Diseases; Physical Therapy Modalities; Treatment Outcome	2020
Dyskinesia and hyperpyrexia syndrome: A case report and review of the literature. Revue neurologique, 2021, Volume: 177, Issue:6 Topics: Dyskinesias; Fever; Humans; Levodopa	2021
Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease: a meta-analysis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021, Volume: 42, Issue:8 Topics: Activities of Daily Living; Antiparkinson Agents; Dyskinesias; Humans; Indoles; Levodopa; Parkinson Disease	2021
Effects of rehabilitation on reducing dyskinesias in a Parkinson's disease patient abusing therapy with levodopa-carbidopa intestinal gel: a paradigmatic case report and literature review. Journal of biological regulators and homeostatic agents, 2021, Aug-27, Volume: 35, Issue:4 Topics: Carbidopa; Drug Combinations; Dyskinesias; Humans; Levodopa; Parkinson Disease	2021
Association of COMT rs4680 and MAO-B rs1799836 polymorphisms with levodopa-induced dyskinesia in Parkinson's disease-a meta-analysis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021, Volume: 42, Issue:10 Topics: Catechol O-Methyltransferase; Dyskinesias; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease	2021
Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease. Chinese medical journal, 2017, Aug-05, Volume: 130, Issue:15 Topics: Clinical Trials as Topic; Dyskinesias; Humans; Levodopa; Parkinson Disease	2017
Efficacy and Safety of Adjuvant Treatment with Entacapone in Advanced Parkinson's Disease with Motor Fluctuation: A Systematic Meta-Analysis. European neurology, 2017, Volume: 78, Issue:3-4 Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Catechols; Drug Therapy, Combination; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease	2017
Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson's disease. Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:14 Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine; Dyskinesias; Humans; Levodopa; Parkinson Disease; Treatment Outcome	2017
Identification of VPS35 p.D620N mutation-related Parkinson's disease in a Taiwanese family with successful bilateral subthalamic nucleus deep brain stimulation: a case report and literature review. BMC neurology, 2017, Oct-06, Volume: 17, Issue:1 Topics: Asian People; Deep Brain Stimulation; Dyskinesias; Female; Genetic Testing; High-Throughput Nucleotide Sequencing; Humans; Levodopa; Middle Aged; Mutation; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome; Vesicular Transport Proteins	2017
Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease. Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:8 Topics: Animals; Antiparkinson Agents; Apomorphine; Dyskinesias; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease	2018
The Pioneering and Unknown Stereotactic Approach of Roeder and Orthner from Göttingen. Part II: Long-Term Outcome and Postmortem Analysis of Bilateral Pallidotomy in the Pre-Levodopa Era. Stereotactic and functional neurosurgery, 2018, Volume: 96, Issue:6 Topics: Adult; Aged; Chorea; Diagnosis; Dyskinesias; Female; Globus Pallidus; Humans; Imaging, Three-Dimensional; Levodopa; Male; Middle Aged; Movement Disorders; Pallidotomy; Parkinson Disease; Psychosurgery; Stereotaxic Techniques; Thalamus; Treatment Outcome; Tremor	2018
Dyskinesia in multiple system atrophy and progressive supranuclear palsy. Journal of neural transmission (Vienna, Austria : 1996), 2019, Volume: 126, Issue:7 Topics: Diagnosis, Differential; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Multiple System Atrophy; Parkinson Disease; Supranuclear Palsy, Progressive	2019
CLINICAL TRIAL HIGHLIGHTS - DYSKINESIA. Journal of Parkinson's disease, 2019, Volume: 9, Issue:3 Topics: Antiparkinson Agents; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Parkinson Disease	2019
Treatment of Parkinson's disease in the advanced stage. Journal of neural transmission (Vienna, Austria : 1996), 2013, Volume: 120, Issue:4 Topics: Antiparkinson Agents; Carbidopa; Dopamine Agonists; Drug Combinations; Dyskinesias; Humans; Levodopa; Parkinson Disease	2013
Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations. Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:8 Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Blood-Brain Barrier; Disease Models, Animal; Dopamine Agonists; Dyskinesias; Half-Life; Humans; Levodopa; Parkinson Disease; Purines; Treatment Outcome	2013
L-DOPA and graft-induced dyskinesia: different treatment, same story? Experimental biology and medicine (Maywood, N.J.), 2013, Volume: 238, Issue:7 Topics: Animals; Cell Transplantation; Disease Models, Animal; Dyskinesias; Humans; Levodopa	2013
[Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2013, Volume: 113, Issue:7 Pt 2 Topics: Antiparkinson Agents; Carbidopa; Catechols; Corpus Striatum; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Humans; Levodopa; Parkinson Disease; Treatment Outcome	2013
Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease. Biochemical Society transactions, 2014, Volume: 42, Issue:2 Topics: Animals; Dyskinesias; Dystonia; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease	2014
Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions. Journal of neurochemistry, 2014, Volume: 130, Issue:4 Topics: Animals; Cannabinoids; Cell Transplantation; Chromatin; Deep Brain Stimulation; Dopamine Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesias; Histones; Humans; Levodopa; Motor Activity; Parkinson Disease; Phosphorylation; Psychomotor Performance; Receptors, Dopamine D1; Signal Transduction; Transcranial Magnetic Stimulation	2014
[Programs for continuing medical education: a session: 4. The pathogenesis and update for the treatments of Parkinson's disease]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Mar-10, Volume: 103, Issue:3 Topics: Benserazide; Benzothiazoles; Catechols; Circadian Rhythm; Dementia; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Drug Tolerance; Dyskinesias; Education, Medical, Continuing; Hallucinations; Humans; Levodopa; Nitriles; Parkinson Disease; Practice Guidelines as Topic; Pramipexole; Reference Standards; Referral and Consultation	2014
Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism & related disorders, 2014, Volume: 20, Issue:9 Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Humans; Levodopa; Parkinson Disease; Receptor, Metabotropic Glutamate 5	2014
Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity. Current medicinal chemistry, 2015, Volume: 22, Issue:36 Topics: Dopamine; Dopaminergic Neurons; Dyskinesias; Humans; Levodopa; Oxidative Stress; Parkinson Disease; Peptides; Peptidomimetics; Prodrugs	2015
[Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2015, Volume: 17, Issue:4 Topics: Antiparkinson Agents; Carbidopa; Dopamine Agents; Dyskinesias; Gastrostomy; Gels; Humans; Intestines; Jejunostomy; Levodopa; Parkinson Disease; Quality of Life	2015
Subthalamic stimulation may inhibit the beneficial effects of levodopa on akinesia and gait. Movement disorders : official journal of the Movement Disorder Society, 2016, Volume: 31, Issue:9 Topics: Adult; Aged; Combined Modality Therapy; Deep Brain Stimulation; Dopamine Agents; Dyskinesias; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Subthalamic Nucleus	2016
An update on the diagnosis and treatment of Parkinson disease. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2016, Nov-01, Volume: 188, Issue:16 Topics: Age of Onset; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Dyskinesias; Humans; Levodopa; Life Expectancy; Parkinson Disease; Practice Guidelines as Topic; Risk Assessment	2016
Levodopa-related motor complications--phenomenology. Movement disorders : official journal of the Movement Disorder Society, 2008, Volume: 23 Suppl 3 Topics: Antiparkinson Agents; Cognition Disorders; Disease Progression; Drug Administration Schedule; Dyskinesias; Fatigue; Humans; Levodopa; Mood Disorders; Motor Activity; Parkinson Disease; Treatment Failure	2008
Levodopa-induced dyskinesias and their management. Journal of neurology, 2008, Volume: 255 Suppl 4 Topics: Antiparkinson Agents; Chorea; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Dyskinesias; Dystonia; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus	2008
[Motor symptoms in Parkinson disease]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2008, Sep-25, Volume: 128, Issue:18 Topics: Age Factors; Antiparkinson Agents; Deep Brain Stimulation; Dopamine Agonists; Dyskinesias; Dystonia; Humans; Levodopa; Muscle Rigidity; Parkinson Disease; Selegiline; Treatment Outcome; Tremor	2008
Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2009, Volume: 6, Issue:1 Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Central Nervous System; Dopamine; Drug Therapy, Combination; Dyskinesias; Haplorhini; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Receptors, Adenosine A2; Xanthines	2009
The effect of onset age on the clinical features of Parkinson's disease. European journal of neurology, 2009, Volume: 16, Issue:4 Topics: Adult; Age of Onset; Aged; Dementia; Disease Progression; Dyskinesia, Drug-Induced; Dyskinesias; Dystonia; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenotype; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome	2009
When and how should treatment be started in Parkinson disease? Neurology, 2009, Feb-17, Volume: 72, Issue:7 Suppl Topics: Antiparkinson Agents; Basal Ganglia; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease	2009
Treatments for Parkinson disease--past achievements and current clinical needs. Neurology, 2009, Feb-17, Volume: 72, Issue:7 Suppl Topics: Adenosine A2 Receptor Antagonists; Adrenergic alpha-Antagonists; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Brain; Cholinesterase Inhibitors; Deep Brain Stimulation; Dopamine Agonists; Dyskinesias; Excitatory Amino Acid Antagonists; History, 20th Century; Humans; Levodopa; Parkinson Disease; Serotonin Agents	2009
Movement disorders in children: recent advances in management. Indian journal of pediatrics, 2009, Volume: 76, Issue:5 Topics: Age Distribution; Age of Onset; Baclofen; Benzodiazepines; Child; Child, Preschool; Cholinergic Antagonists; Dopamine Agents; Drug Therapy, Combination; Dyskinesias; Early Diagnosis; Electromyography; Female; Humans; Incidence; Infant; Levodopa; Male; Movement Disorders; Physical Examination; Prognosis; Risk Assessment; Severity of Illness Index; Sex Distribution; Spain; Treatment Outcome	2009
Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease. CNS drugs, 2010, Volume: 24, Issue:2 Topics: Administration, Oral; Clinical Protocols; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease; Treatment Outcome	2010
Synaptic dysfunction in Parkinson's disease. Biochemical Society transactions, 2010, Volume: 38, Issue:2 Topics: Animals; Antiparkinson Agents; Basal Ganglia; Carrier Proteins; Dyskinesias; Humans; Levodopa; Nerve Tissue Proteins; Neuronal Plasticity; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Synapses; Synaptic Transmission	2010
Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio). Clinical neuropharmacology, 2010, Volume: 33, Issue:4 Topics: Antiparkinson Agents; Biological Availability; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Hyperkinesis; Levodopa; Male; Parkinson Disease; Solubility; Time Factors	2010
Classifying risk factors for dyskinesia in Parkinson's disease. Parkinsonism & related disorders, 2010, Volume: 16, Issue:8 Topics: Age Factors; Antiparkinson Agents; Dyskinesias; Female; Humans; Levodopa; Male; Parkinson Disease; Risk Factors; Sex Factors	2010
Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. The Cochrane database of systematic reviews, 2010, Jul-07, Issue:7 Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Chemotherapy, Adjuvant; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic	2010
Consensus paper: use of transcranial magnetic stimulation to probe motor cortex plasticity in dystonia and levodopa-induced dyskinesia. Brain stimulation, 2009, Volume: 2, Issue:2 Topics: Animals; Basal Ganglia; Dyskinesias; Dystonic Disorders; Hand; Humans; Levodopa; Models, Neurological; Motor Cortex; Neuronal Plasticity; Transcranial Magnetic Stimulation	2009
Management of motor complications in Parkinson disease: current and emerging therapies. Neurologic clinics, 2010, Volume: 28, Issue:4 Topics: Deep Brain Stimulation; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Parkinson Disease	2010
Understanding graft-induced dyskinesia. Regenerative medicine, 2010, Volume: 5, Issue:5 Topics: Cell Transplantation; Dyskinesias; Humans; Levodopa; Parkinson Disease	2010
Motor complications, levodopa metabolism and progression of Parkinson's disease. Expert opinion on drug metabolism & toxicology, 2011, Volume: 7, Issue:7 Topics: Animals; Arteriosclerosis; Catechol O-Methyltransferase; Disease Progression; Dopamine; Dyskinesias; Enzyme Inhibitors; Free Radicals; Homocysteine; Humans; Levodopa; Nerve Degeneration; Parkinson Disease; Synaptic Transmission	2011
Treatment of motor symptoms in advanced Parkinson's disease: a practical approach. Progress in neuro-psychopharmacology & biological psychiatry, 2011, Dec-01, Volume: 35, Issue:8 Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Parkinson Disease	2011
Factors related to functional independence in females with Parkinson's disease: a systematic review. Maturitas, 2011, Volume: 69, Issue:4 Topics: Activities of Daily Living; Dyskinesias; Female; Gait; Humans; Levodopa; Male; Parkinson Disease; Postural Balance; Psychomotor Performance; Quality of Life; Sex Factors	2011
l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment. International review of neurobiology, 2011, Volume: 98 Topics: Animals; Antiparkinson Agents; Dyskinesias; History, 20th Century; Humans; Levodopa; Parkinson Disease; Risk Factors	2011
[Stimulation therapies for Parkinson's disease: over the past two decades]. Bulletin de l'Academie nationale de medecine, 2010, Volume: 194, Issue:7 Topics: Animals; Cytoprotection; Deep Brain Stimulation; Dyskinesias; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus; Time Factors	2010
Continuous dopaminergic stimulation: clinical aspects and experimental bases. The neurologist, 2011, Volume: 17, Issue:6 Suppl 1 Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Neuropeptides; Parkinson Disease; Receptors, Dopamine; Receptors, GABA-A	2011
New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors. Expert opinion on investigational drugs, 2012, Volume: 21, Issue:2 Topics: Animals; Antiparkinson Agents; Dyskinesias; Excitatory Amino Acid Antagonists; Humans; Levodopa; Parkinson Disease; Purinergic P1 Receptor Antagonists; Receptors, Glutamate; Receptors, Purinergic P1	2012
Off spells and dyskinesias: pharmacologic management of motor complications. Cleveland Clinic journal of medicine, 2012, Volume: 79 Suppl 2 Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Receptors, Dopamine	2012
L-DOPA- and graft-induced dyskinesia following transplantation. Progress in brain research, 2012, Volume: 200 Topics: Animals; Antiparkinson Agents; Brain Tissue Transplantation; Disease Models, Animal; Dyskinesias; Humans; Levodopa; Parkinson Disease	2012
Two advances in the management of Parkinson disease. Cleveland Clinic journal of medicine, 2002, Volume: 69, Issue:8 Topics: Age Factors; Antiparkinson Agents; Benzothiazoles; Carbidopa; Dyskinesias; Electric Stimulation Therapy; Forecasting; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Risk Factors; Stereotaxic Techniques; Thiazoles	2002
Which factors influence therapeutic decisions in Parkinson's disease? Journal of neurology, 2002, Volume: 249 Suppl 3 Topics: Age Factors; Dopamine Agonists; Drug Interactions; Dyskinesias; Evidence-Based Medicine; Excitatory Amino Acid Antagonists; Health Care Costs; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Quality of Life; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Risk Factors	2002
The fluctuating Parkinsonian patient--clinical and pathophysiological aspects. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2003, Volume: 30 Suppl 1 Topics: Animals; Drug Administration Schedule; Dyskinesias; Haplorhini; Humans; Levodopa; Parkinson Disease; Rats; Receptors, Dopamine; Receptors, GABA; Receptors, N-Methyl-D-Aspartate; Receptors, Neurotransmitter; Receptors, Opioid	2003
Treatment of Parkinson's disease. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2003, Volume: 30 Suppl 1 Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesias; Holistic Health; Humans; Levodopa; Musculoskeletal Manipulations; Neuroprotective Agents; Occupational Therapy; Parkinson Disease; Speech Therapy	2003
Motor complications of Parkinson's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2003, Volume: 24 Suppl 1 Topics: Drug Resistance; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Hypokinesia; Levodopa; Parkinson Disease; Treatment Failure	2003
Prevention and treatment of motor fluctuations. Parkinsonism & related disorders, 2003, Volume: 9 Suppl 2 Topics: Antiparkinson Agents; Apomorphine; Benzophenones; Dyskinesias; Enzyme Inhibitors; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone	2003
Long-term L-DOPA therapy: challenges to our understanding and for the care of people with Parkinson's disease. Experimental neurology, 2003, Volume: 184, Issue:1 Topics: Antiparkinson Agents; Disease Progression; Dopamine; Dyskinesias; Dystonia; Humans; Levodopa; Long-Term Care; Parkinson Disease	2003
Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: potential targets for a new therapeutic approach. Experimental neurology, 2003, Volume: 184, Issue:2 Topics: Animals; Antiparkinson Agents; Brain; Dyskinesias; Humans; Levodopa; Parkinson Disease; Purinergic P1 Receptor Antagonists; Receptors, Purinergic P1	2003
Deep brain stimulation in the treatment of dyskinesia and dystonia. Neurosurgical focus, 2004, Jul-15, Volume: 17, Issue:1 Topics: Dyskinesia, Drug-Induced; Dyskinesias; Dystonic Disorders; Electric Stimulation Therapy; Electrodes, Implanted; Globus Pallidus; Humans; Levodopa; Molecular Chaperones; Parkinson Disease; Stereotaxic Techniques; Subthalamic Nucleus; Treatment Outcome	2004
Comparison of pallidal and subthalamic deep brain stimulation for the treatment of levodopa-induced dyskinesias. Neurosurgical focus, 2004, Jul-15, Volume: 17, Issue:1 Topics: Antiparkinson Agents; Combined Modality Therapy; Dyskinesia, Drug-Induced; Dyskinesias; Electric Stimulation Therapy; Electrodes, Implanted; Globus Pallidus; Humans; Levodopa; Organ Specificity; Parkinson Disease; Subthalamic Nucleus; Thalamus; Treatment Outcome	2004
Peculiarities of L: -DOPA treatment of Parkinson's disease. Amino acids, 2005, Volume: 28, Issue:2 Topics: Animals; Antiparkinson Agents; Basal Ganglia; Biological Transport; Brain Chemistry; Dopamine; Dyskinesias; Humans; Hydroxyl Radical; Levodopa; Parkinson Disease; Rats; Receptors, Dopamine	2005
A walk through the management of Parkinson s disease. Annals of the Academy of Medicine, Singapore, 2005, Volume: 34, Issue:2 Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Deep Brain Stimulation; Disease Progression; Dopamine; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Receptors, Dopamine	2005
New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. Life sciences, 2005, Nov-12, Volume: 77, Issue:26 Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Humans; Levodopa; Parkinson Disease; Primates; Purines; Receptor, Adenosine A2A	2005
Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21 Suppl 14 Topics: Deep Brain Stimulation; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Parkinson Disease; Postoperative Complications; Quality of Life; Subthalamic Nucleus; Treatment Outcome	2006
Levodopa, motor fluctuations and dyskinesia in Parkinson's disease. Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:13 Topics: Animals; Disease Progression; Dyskinesias; Humans; Levodopa; Motor Neuron Disease; Parkinson Disease; Risk Factors	2006
Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa? Movement disorders : official journal of the Movement Disorder Society, 2007, Volume: 22, Issue:1 Topics: Animals; Dopamine; Dopamine Agents; Dyskinesias; Humans; Levodopa; Parkinson Disease; Pulse Therapy, Drug	2007
Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert review of neurotherapeutics, 2006, Volume: 6, Issue:10 Topics: Carbidopa; Dyskinesias; Gels; Humans; Infusion Pumps; Infusions, Parenteral; Levodopa; Parkinson Disease	2006
[Medical treatment of Parkinson's disease]. Therapeutische Umschau. Revue therapeutique, 2007, Volume: 64, Issue:1 Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Cholinergic Antagonists; Controlled Clinical Trials as Topic; Dementia; Depression; Dopamine Agents; Dopamine Agonists; Drug Therapy, Combination; Dyskinesias; Hallucinations; Humans; Levodopa; Middle Aged; Multicenter Studies as Topic; Pain; Parkinson Disease; Quality of Life; Therapeutic Equivalency; Time Factors	2007
[Dyskinesia in Parkinson's disease--major clinical features, aetiology, therapy]. Fortschritte der Neurologie-Psychiatrie, 2007, Volume: 75, Issue:7 Topics: Antiparkinson Agents; Basal Ganglia; Dyskinesias; Humans; Levodopa; Neuroprotective Agents; Neurosurgical Procedures; Parkinson Disease; Quality of Life; Risk Factors	2007
Management for motor and non-motor complications in late Parkinson's disease. Geriatrics, 2008, Volume: 63, Issue:5 Topics: Accidental Falls; Aged; Antiparkinson Agents; Comorbidity; Dementia; Dyskinesias; Humans; Hypotension, Orthostatic; Levodopa; Parkinson Disease; Sleep Wake Disorders	2008
Ropinirole for levodopa-induced complications in Parkinson's disease. The Cochrane database of systematic reviews, 2000, Issue:3 Topics: Antiparkinson Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dopamine Agonists; Dyskinesias; Humans; Indoles; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic	2000
Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease. The Cochrane database of systematic reviews, 2000, Issue:3 Topics: Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Dyskinesias; Humans; Indoles; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic	2000
[Physiopathology of parkinsonism and dyskinesias: lessons from surgical observations]]. Neurologia (Barcelona, Spain), 2001, Volume: 16, Issue:1 Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dyskinesia, Drug-Induced; Dyskinesias; Globus Pallidus; Humans; Levodopa; Models, Animal; Models, Neurological; Motor Skills; Neurons; Parkinsonian Disorders; Subthalamic Nucleus; Thalamus	2001
Ropinirole for levodopa-induced complications in Parkinson's disease. The Cochrane database of systematic reviews, 2001, Issue:1 Topics: Antiparkinson Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dopamine Agonists; Dyskinesias; Humans; Indoles; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic	2001
Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease. The Cochrane database of systematic reviews, 2001, Issue:1 Topics: Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Dyskinesias; Humans; Indoles; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic	2001
Motor fluctuations and dyskinesia in Parkinson's disease. Parkinsonism & related disorders, 2001, Volume: 8, Issue:2 Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Movement; Parkinson Disease	2001
Use of selective thalamotomy for various kinds of movement disorder, based on basic studies. Stereotactic and functional neurosurgery, 2000, Volume: 75, Issue:2-3 Topics: Antiparkinson Agents; Cerebral Hemorrhage; Chorea; Dyskinesia, Drug-Induced; Dyskinesias; Dystonia; Electrodes, Implanted; Electroencephalography; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Movement Disorders; Muscle Rigidity; Paresthesia; Parkinson Disease; Postoperative Complications; Stereotaxic Techniques; Surgery, Computer-Assisted; Thalamic Nuclei; Tomography, X-Ray Computed; Treatment Outcome; Tremor	2000

Trials

48 trial(s) available for levodopa and Abnormal Movements

Article	Year
Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials. Journal of the neurological sciences, 2021, Nov-15, Volume: 430 Topics: Antiparkinson Agents; Double-Blind Method; Dyskinesias; Humans; Levodopa; Parkinson Disease; Zonisamide	2021
A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society, 2022, Volume: 37, Issue:5 Topics: Antiparkinson Agents; Double-Blind Method; Dyskinesias; Humans; Levodopa; Parkinson Disease	2022
Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson's disease: post-hoc analysis of a Japanese phase III study. Journal of neural transmission (Vienna, Austria : 1996), 2022, Volume: 129, Issue:10 Topics: Alanine; Antiparkinson Agents; Benzylamines; Dyskinesias; Humans; Japan; Levodopa; Parkinson Disease; Treatment Outcome	2022
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial. The Lancet. Neurology, 2022, Volume: 21, Issue:12 Topics: Antiparkinson Agents; Carbidopa; Cellulitis; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Parkinson Disease	2022
Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients. Journal of Parkinson's disease, 2020, Volume: 10, Issue:1 Topics: Activities of Daily Living; Aged; Alanine; Antiparkinson Agents; Benzylamines; Double-Blind Method; Drug Therapy, Combination; Dyskinesias; Female; Glutamic Acid; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life; Severity of Illness Index	2020
Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Neurology, 2020, Volume: 19, Issue:2 Topics: Administration, Sublingual; Adult; Aged; Antiparkinson Agents; Apomorphine; Canada; Double-Blind Method; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome; United States	2020
Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial. Movement disorders : official journal of the Movement Disorder Society, 2021, Volume: 36, Issue:11 Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life	2021
A Transitional Probability Model for Parkinson's Disease Motor States With Applications to Missing Data. Therapeutic innovation & regulatory science, 2019, Volume: 53, Issue:4 Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Double-Blind Method; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Markov Chains; Middle Aged; Models, Statistical; Movement; Parkinson Disease	2019
Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease. Journal of clinical pharmacology, 2013, Volume: 53, Issue:5 Topics: Antiparkinson Agents; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Models, Biological; Parkinson Disease	2013
[Nocturnal symptoms of Parkinson's disease and approaches to their correction]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2013, Volume: 113, Issue:12 Topics: Carbidopa; Catechols; Drug Combinations; Dyskinesias; Humans; Levodopa; Muscle Cramp; Nocturia; Parkinson Disease; Restless Legs Syndrome	2013
Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease. Parkinsonism & related disorders, 2014, Volume: 20, Issue:12 Topics: Administration, Cutaneous; Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesias; Female; Humans; Kaplan-Meier Estimate; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Sex Factors; Tetrahydronaphthalenes; Thiophenes	2014
Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis. Journal of Parkinson's disease, 2015, Volume: 5, Issue:3 Topics: Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesias; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Severity of Illness Index; Treatment Outcome	2015
What is a clinically important change in the Unified Dyskinesia Rating Scale in Parkinson's disease? Parkinsonism & related disorders, 2015, Volume: 21, Issue:11 Topics: Aged; Clinical Trials, Phase II as Topic; Dopamine Agents; Double-Blind Method; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Outcome Assessment	2015
Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2016, Volume: 25 Topics: Adult; Aged; Antiparkinson Agents; Australia; Carbidopa; Dopamine Agents; Duodenum; Dyskinesias; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peripheral Nervous System Diseases; Prospective Studies; Psychomotor Performance; Quality of Life	2016
Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease? Movement disorders : official journal of the Movement Disorder Society, 2008, Sep-15, Volume: 23, Issue:12 Topics: Aged; Antiparkinson Agents; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Pain; Pain Measurement; Pain Threshold; Parkinsonian Disorders; Severity of Illness Index; Time Factors	2008
Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. Movement disorders : official journal of the Movement Disorder Society, 2008, Oct-15, Volume: 23, Issue:13 Topics: Aged; Cross-Over Studies; Dopamine Agents; Double-Blind Method; Dyskinesias; Excitatory Amino Acid Antagonists; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Piperidines; Severity of Illness Index	2008
Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial). Neuroscience and behavioral physiology, 2008, Volume: 38, Issue:9 Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Outpatients; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome	2008
Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Movement disorders : official journal of the Movement Disorder Society, 2009, Feb-15, Volume: 24, Issue:3 Topics: Antiparkinson Agents; Cell Transplantation; Double-Blind Method; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors; Severity of Illness Index; Substantia Nigra; Videotape Recording	2009
Longitudinal study of the levodopa motor response in Parkinson's disease: relationship between cognitive decline and motor function. Movement disorders : official journal of the Movement Disorder Society, 2009, Dec-15, Volume: 24, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Cognition Disorders; Dementia; Disability Evaluation; Dyskinesias; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Parkinsonian Disorders; Statistics, Nonparametric	2009
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study. Journal of neural transmission (Vienna, Austria : 1996), 2010, Volume: 117, Issue:3 Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechols; Drug-Related Side Effects and Adverse Reactions; Dyskinesias; Feasibility Studies; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome	2010
Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia. Neuroscience and behavioral physiology, 2010, Volume: 40, Issue:2 Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cognition; Cognition Disorders; Dementia; Disability Evaluation; Dyskinesias; Homocysteine; Humans; Levodopa; Memantine; Neuropsychological Tests; Nootropic Agents; Parkinson Disease; Psychiatric Status Rating Scales; Receptors, N-Methyl-D-Aspartate; Treatment Outcome	2010
Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. Clinical neuropharmacology, 2010, Volume: 33, Issue:3 Topics: Age of Onset; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nitrophenols; Parkinson Disease; Severity of Illness Index; Tolcapone; Tyrosine	2010
Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study. Clinical neuropharmacology, 2010, Volume: 33, Issue:3 Topics: Aged; Ambulatory Care Facilities; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Feasibility Studies; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Severity of Illness Index; Time Factors; Tolcapone; Treatment Outcome	2010
Long-term stability of effects of subthalamic stimulation in Parkinson's disease: Indian Experience. Movement disorders : official journal of the Movement Disorder Society, 2010, Oct-30, Volume: 25, Issue:14 Topics: Adult; Antiparkinson Agents; Attention; Cognition Disorders; Deep Brain Stimulation; Dyskinesias; Executive Function; Female; Humans; India; Levodopa; Longitudinal Studies; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Quality of Life; Retrospective Studies; Single-Blind Method; Subthalamic Nucleus; Time Factors; Treatment Outcome	2010
A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease. Parkinsonism & related disorders, 2011, Volume: 17, Issue:7 Topics: Aged; Antiparkinson Agents; Catechols; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesias; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Single-Blind Method	2011
Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation. European journal of neurology, 2012, Volume: 19, Issue:1 Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Dyskinesias; Female; Humans; Hypodermoclysis; Infusions, Parenteral; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease	2012
Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study. Parkinsonism & related disorders, 2013, Volume: 19, Issue:1 Topics: Adult; Behavior; Deep Brain Stimulation; Dyskinesias; Electric Stimulation Therapy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Risk; Subthalamic Nucleus; Surveys and Questionnaires; Treatment Outcome; Young Adult	2013
Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain : a journal of neurology, 2002, Volume: 125, Issue:Pt 9 Topics: Administration, Oral; Antiparkinson Agents; Dyskinesias; Home Infusion Therapy; Humans; Levodopa; Lisuride; Middle Aged; Parkinson Disease; Prospective Studies; Severity of Illness Index	2002
Subthalamotomy for advanced Parkinson disease. Journal of neurosurgery, 2002, Volume: 97, Issue:3 Topics: Aged; Antiparkinson Agents; Dyskinesias; Female; Functional Laterality; Humans; Hypokinesia; Levodopa; Magnetic Resonance Imaging; Male; Microelectrodes; Middle Aged; Parkinson Disease; Postoperative Complications; Radiosurgery; Subthalamic Nucleus; Treatment Outcome; Tremor	2002
Subthalamic nucleus stimulation for Parkinson's disease preferentially improves akinesia of proximal arm movements compared to finger movements. Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:10 Topics: Antiparkinson Agents; Arm; Dyskinesias; Electric Stimulation Therapy; Fingers; Hand Strength; Humans; Levodopa; Movement; Parkinson Disease; Subthalamic Nucleus; Time Factors	2003
Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 2004, Volume: 75, Issue:1 Topics: Aged; Amantadine; Dopamine Agents; Double-Blind Method; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome	2004
The dopamine transporter: importance in Parkinson's disease. Annals of neurology, 2004, Volume: 55, Issue:6 Topics: Aged; Analysis of Variance; Blood Pressure; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Routes; Drug Synergism; Dyskinesias; Emotions; Female; Heart Rate; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Methylphenidate; Middle Aged; Motor Activity; Nerve Tissue Proteins; Parkinson Disease; Parkinsonian Disorders; Psychomotor Performance; Time Factors; Walking	2004
Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease 4 years after surgery: double blind and open label evaluation. Journal of neurology, neurosurgery, and psychiatry, 2004, Volume: 75, Issue:10 Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesias; Electric Stimulation Therapy; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome	2004
Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:2 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesias; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Pain Measurement; Parkinson Disease; Prospective Studies; Self-Assessment; Statistics, Nonparametric	2005
Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology, 2004, Oct-12, Volume: 63, Issue:7 Topics: Aged; Antiparkinson Agents; Cannabis; Cross-Over Studies; Double-Blind Method; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Plant Extracts	2004
Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. Journal of neurology, neurosurgery, and psychiatry, 2004, Volume: 75, Issue:12 Topics: Administration, Oral; Aged; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Mucuna; Parkinson Disease; Phytotherapy; Placebos; Plant Preparations; Seeds; Severity of Illness Index; Treatment Outcome	2004
Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Archives of neurology, 2005, Volume: 62, Issue:6 Topics: Administration, Oral; Aged; Aged, 80 and over; Drug Administration Schedule; Dyskinesias; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies	2005
Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:3 Topics: Adult; Age of Onset; Aged; Brain; Dopamine Agonists; Double-Blind Method; Dyskinesias; Early Diagnosis; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Prospective Studies; Radionuclide Imaging; Surveys and Questionnaires	2006
Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Archives of neurology, 2006, Volume: 63, Issue:12 Topics: Age of Onset; Aged; Antiparkinson Agents; Benzothiazoles; Double-Blind Method; Dyskinesias; Female; Humans; Levodopa; Logistic Models; Male; Middle Aged; Parkinson Disease; Pramipexole; Proportional Hazards Models; Prospective Studies; Retrospective Studies	2006
Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Movement disorders : official journal of the Movement Disorder Society, 2007, Jun-15, Volume: 22, Issue:8 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Administration Schedule; Drug Therapy, Combination; Duodenum; Dyskinesias; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome	2007
Posteroventral pallidotomy in Parkinson's disease. Acta neurochirurgica, 2000, Volume: 142, Issue:2 Topics: Aged; Antiparkinson Agents; Dyskinesias; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Speech Disorders; Treatment Outcome	2000
The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa. Movement disorders : official journal of the Movement Disorder Society, 2000, Volume: 15, Issue:5 Topics: Administration, Oral; Aged; Analysis of Variance; Antiparkinson Agents; Cross-Over Studies; Dyskinesias; Exercise; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index	2000
Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA, 2000, Oct-18, Volume: 284, Issue:15 Topics: Antiparkinson Agents; Benzothiazoles; Carrier Proteins; Cocaine; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Double-Blind Method; Dyskinesias; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Pramipexole; Proportional Hazards Models; Quality of Life; Radiopharmaceuticals; Thiazoles; Tomography, Emission-Computed, Single-Photon	2000
Dorsal subthalamotomy for Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2001, Volume: 16, Issue:1 Topics: Aged; Antiparkinson Agents; Dyskinesias; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Pilot Projects; Postoperative Period; Subthalamic Nucleus	2001
Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Archives of neurology, 2001, Volume: 58, Issue:10 Topics: Acetamides; Activities of Daily Living; Anticonvulsants; Dyskinesias; Humans; Informed Consent; Levodopa; Medical Records; Mental Status Schedule; Middle Aged; Motor Activity; Neuroprotective Agents; Parkinson Disease; Pilot Projects; Placebos; Reproducibility of Results; Treatment Outcome	2001
Chronic bilateral pallidal stimulation and levodopa do not improve gait in the same way in Parkinson's disease: a study using a video motion analysis system. Journal of neurology, 2001, Volume: 248, Issue:11 Topics: Aged; Antiparkinson Agents; Dyskinesias; Electric Stimulation Therapy; Female; Gait; Globus Pallidus; Humans; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome	2001
High-dose therapy with ropinirole in patients with Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2001, Volume: 108, Issue:11 Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesias; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Prospective Studies	2001
[Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease]. No to shinkei = Brain and nerve, 2002, Volume: 54, Issue:2 Topics: Adult; Aged; Dyskinesias; Female; Humans; Isoindoles; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Pyrimidines; Serotonin Receptor Agonists; Treatment Outcome	2002

Other Studies

279 other study(ies) available for levodopa and Abnormal Movements

Article	Year
A new target for Parkinson's disease: Small molecule SERCA activator CDN1163 ameliorates dyskinesia in 6-OHDA-lesioned rats. Bioorganic & medicinal chemistry, 2017, 01-01, Volume: 25, Issue:1 Topics: Aminoquinolines; Animals; Benzamides; Calcium; Cell Death; Drug Discovery; Dyskinesias; Endoplasmic Reticulum Stress; Enzyme Activators; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Sarcoplasmic Reticulum Calcium-Transporting ATPases	2017
Premorbid Educational Attainment and Long-Term Motor Prognosis in Parkinson's Disease. Journal of Parkinson's disease, 2022, Volume: 12, Issue:1 Topics: Dyskinesias; Humans; Levodopa; Parkinson Disease; Prognosis; Putamen	2022
Dopaminergic co-transmission with sonic hedgehog inhibits abnormal involuntary movements in models of Parkinson's disease and L-Dopa induced dyskinesia. Communications biology, 2021, 09-22, Volume: 4, Issue:1 Topics: Animals; Disease Models, Animal; Dopamine; Dyskinesias; Female; Hedgehog Proteins; Levodopa; Male; Mice; Parkinson Disease	2021
Influence of istradefylline on non-motor symptoms of Parkinson's disease: A subanalysis of a 1-year observational study in Japan (J-FIRST). Parkinsonism & related disorders, 2021, Volume: 91 Topics: Aged; Antiparkinson Agents; Dyskinesias; Female; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Purines; Quality of Life; Surveys and Questionnaires; Treatment Outcome	2021
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease. Journal of visualized experiments : JoVE, 2021, 10-14, Issue:176 Topics: Animals; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Levodopa; Oxidopamine; Parkinson Disease; Rats	2021
Spontaneous Graft-Induced Dyskinesias Are Independent of 5-HT Neurons and Levodopa Priming in a Model of Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society, 2022, Volume: 37, Issue:3 Topics: Animals; Antiparkinson Agents; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin	2022
Effect of onset age on the levodopa threshold dosage for dyskinesia in Parkinson's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022, Volume: 43, Issue:5 Topics: Age of Onset; Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Parkinson Disease; ROC Curve	2022
[Clinical picture of patients with Parkinson's disease attending a regional core hospital in Ehime]. Rinsho shinkeigaku = Clinical neurology, 2022, Jan-28, Volume: 62, Issue:1 Topics: Aged; Antiparkinson Agents; Dyskinesias; Female; Hospitals; Humans; Levodopa; Male; Parkinson Disease	2022
Levodopa-induced dyskinesias in Parkinson's disease increase cerebrospinal fluid nitric oxide metabolites' levels. Journal of neural transmission (Vienna, Austria : 1996), 2022, Volume: 129, Issue:1 Topics: Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Nitric Oxide; Parkinson Disease	2022
Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel. Journal of Parkinson's disease, 2022, Volume: 12, Issue:3 Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Gels; Humans; Levodopa; Parkinson Disease; Prospective Studies; Quality of Life	2022
Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022, Volume: 43, Issue:5 Topics: Alanine; Benzylamines; Deep Brain Stimulation; Dyskinesias; Humans; Levodopa; Pain; Parkinson Disease; Quality of Life; Subthalamic Nucleus; Treatment Outcome	2022
Propofol Withdrawal Dyskinesia in a Parkinson's Disease Patient with Levodopa-Induced Dyskinesia. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2023, Volume: 50, Issue:2 Topics: Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Parkinson Disease; Propofol	2023
COVID-19 infection presented as severe dyskinesia in a patient with Parkinson's disease: a case with daily video recording. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022, Volume: 43, Issue:5 Topics: Antiparkinson Agents; COVID-19; Dyskinesias; Humans; Levodopa; Parkinson Disease; Video Recording	2022
Striatal Indirect Pathway Dysfunction Underlies Motor Deficits in a Mouse Model of Paroxysmal Dyskinesia. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2022, 03-30, Volume: 42, Issue:13 Topics: Animals; Chorea; Corpus Striatum; Disease Models, Animal; Dyskinesias; Female; Levodopa; Male; Mice; Neurons	2022
Risk factors for motor complications in female patients with Parkinson's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022, Volume: 43, Issue:8 Topics: Antiparkinson Agents; Dyskinesias; Female; Humans; Levodopa; Multivariate Analysis; Parkinson Disease; Risk Factors	2022
Continuous Dopaminergic Stimulation Improves Cortical Maladaptive Changes in Advanced Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society, 2022, Volume: 37, Issue:7 Topics: Carbidopa; Dopamine; Dyskinesias; Humans; Levodopa; Motor Cortex; Parkinson Disease	2022
The Chinese Parkinson's Disease Registry (CPDR): Study Design and Baseline Patient Characteristics. Movement disorders : official journal of the Movement Disorder Society, 2022, Volume: 37, Issue:7 Topics: Age of Onset; Cross-Sectional Studies; Dyskinesias; Female; Humans; Levodopa; Male; Parkinson Disease; Registries	2022
Sensitivity to gait improvement after levodopa intake in Parkinson's disease: A comparison study among synthetic kinematic indices. PloS one, 2022, Volume: 17, Issue:5 Topics: Antiparkinson Agents; Biomechanical Phenomena; Dyskinesias; Gait; Humans; Levodopa; Parkinson Disease	2022
[Dyskinesia-hyperpyrexia syndrome triggered by overdose of istradefylline: a case report]. Rinsho shinkeigaku = Clinical neurology, 2022, Aug-27, Volume: 62, Issue:8 Topics: Aged; Antiparkinson Agents; Drug Overdose; Dyskinesias; Female; Fever; Humans; Levodopa; Parkinson Disease; Purines	2022
Ten-year trends of the characteristics in patients with advanced Parkinson's disease at the time of intestinal gel therapy introduction Orvosi hetilap, 2022, Jul-24, Volume: 163, Issue:30 Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Gels; Humans; Levodopa; Male; Neurodegenerative Diseases; Parkinson Disease; Retrospective Studies	2022
Identifying the therapeutic zone in globus pallidus deep brain stimulation for Parkinson's disease. Journal of neurosurgery, 2023, 02-01, Volume: 138, Issue:2 Topics: Deep Brain Stimulation; Dyskinesias; Electrodes, Implanted; Globus Pallidus; Humans; Levodopa; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome	2023
Clinical correlates of movement disorders in adult Niemann-Pick type C patients measured via a Personal KinetiGraph. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022, Volume: 43, Issue:11 Topics: Adult; Dyskinesias; Humans; Hypokinesia; Levodopa; Niemann-Pick Disease, Type C; Parkinson Disease	2022
Does dopamine deficiency affect sex-dependent prognosis in Parkinson's disease? Parkinsonism & related disorders, 2022, Volume: 102 Topics: Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Parkinson Disease; Prognosis	2022
Adenosine A Journal of neurology, 2023, Volume: 270, Issue:1 Topics: Adenosine; Dyskinesias; Humans; Levodopa; Parkinson Disease; Receptor, Adenosine A2A	2023
How resistant are levodopa-resistant axial symptoms? Response of freezing, posture, and voice to increasing levodopa intestinal infusion rates in Parkinson disease. European journal of neurology, 2023, Volume: 30, Issue:1 Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Gait Disorders, Neurologic; Gels; Humans; Levodopa; Middle Aged; Parkinson Disease; Posture	2023
Pharmacological targeting of G protein-coupled receptor heteromers. Pharmacological research, 2022, Volume: 185 Topics: Animals; Dopamine; Dyskinesias; Levodopa; Ligands; Mice; Rats; Receptors, Dopamine D1; Receptors, Dopamine D3; Receptors, G-Protein-Coupled	2022
Agmatine-mediated inhibition of NMDA receptor expression and amelioration of dyskinesia via activation of Nrf2 and suppression of HMGB1/RAGE/TLR4/MYD88/NF-κB signaling cascade in rotenone lesioned rats. Life sciences, 2022, Dec-15, Volume: 311, Issue:Pt A Topics: Agmatine; Animals; Antioxidants; Dyskinesias; HMGB1 Protein; Levodopa; Myeloid Differentiation Factor 88; NF-E2-Related Factor 2; NF-kappa B; Oxidopamine; Parkinson Disease; Rats; Receptors, N-Methyl-D-Aspartate; Rotenone; Signal Transduction; Toll-Like Receptor 4	2022
Amino acid transporter Asc-1 (SLC7A10) expression is altered in basal ganglia in experimental Parkinsonism and L-dopa-induced dyskinesia model mice. Journal of chemical neuroanatomy, 2023, Volume: 127 Topics: Amino Acid Transport System ASC; Amino Acid Transport System y+; Animals; Basal Ganglia; Dopamine; Dyskinesias; Levodopa; Mice; Parkinson Disease; Parkinsonian Disorders; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Serine	2023
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias. Neurobiology of disease, 2023, Volume: 176 Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Levodopa; Mice; Oxidopamine; Parkinson Disease	2023
Quantitative Transcranial Sonography Evaluation of Substantia Nigra Hyperechogenicity Is Useful for Predicting Levodopa-Induced Dyskinesia in Parkinson Disease. Ultrasound in medicine & biology, 2023, Volume: 49, Issue:2 Topics: Dyskinesias; Humans; Levodopa; Parkinson Disease; Substantia Nigra; Ultrasonography; Ultrasonography, Doppler, Transcranial	2023
Long-term motor outcomes of deep brain stimulation of the globus pallidus interna in Parkinson's disease patients: Five-year follow-up. Journal of the neurological sciences, 2023, 01-15, Volume: 444 Topics: Aged; Deep Brain Stimulation; Dyskinesias; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Middle Aged; Parkinson Disease; Retrospective Studies; Treatment Outcome; Tremor	2023
Moving chin left and right: levodopa induced dyskinesia in spinocerebellar ataxia type 3? Acta neurologica Belgica, 2023, Volume: 123, Issue:6 Topics: Antiparkinson Agents; Chin; Dyskinesias; Humans; Levodopa; Machado-Joseph Disease; Parkinson Disease	2023
A case report of Parkinson's disease with acute and unmanageable myoclonic dyskinesia. Clinical neurology and neurosurgery, 2023, Volume: 226 Topics: Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Parkinson Disease	2023
Multimodal Imaging of Substantia Nigra in Parkinson's Disease with Levodopa-Induced Dyskinesia. Movement disorders : official journal of the Movement Disorder Society, 2023, Volume: 38, Issue:4 Topics: Dyskinesias; Humans; Levodopa; Magnetic Resonance Imaging; Multimodal Imaging; Parkinson Disease; Substantia Nigra	2023
Effects of Dihydropyridines on the Motor and Cognitive Outcomes of Patients with Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society, 2023, Volume: 38, Issue:5 Topics: Antiparkinson Agents; Cognition; Dihydropyridines; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Humans; Hypertension; Levodopa; Parkinson Disease	2023
Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease. Arquivos de neuro-psiquiatria, 2023, Volume: 81, Issue:1 Topics: Antiparkinson Agents; Dyskinesias; Female; Humans; Levodopa; Male; Parkinson Disease; Uric Acid	2023
Timely referral for device-aided therapy in Parkinson's disease. Development of a screening tool. Parkinsonism & related disorders, 2023, Volume: 109 Topics: Antiparkinson Agents; Cross-Sectional Studies; Dyskinesias; Humans; Levodopa; Parkinson Disease; Referral and Consultation	2023
Risk factors for developing dyskinesia among Parkinson's disease patients with wearing-off: J-FIRST. Journal of the neurological sciences, 2023, 05-15, Volume: 448 Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Dopamine Agonists; Dyskinesias; Female; Humans; Levodopa; Parkinson Disease; Quality of Life; Risk Factors; Zonisamide	2023
15-Year Subthalamic Deep Brain Stimulation outcome in a Parkinson's disease patient with Parkin gene mutation: a case report. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2023, Volume: 44, Issue:8 Topics: Adult; Deep Brain Stimulation; Dyskinesias; Humans; Levodopa; Male; Mutation; Parkinson Disease; Pramipexole; Quality of Life; Subthalamic Nucleus; Treatment Outcome	2023
Doxycycline to treat levodopa-induced dyskinesias in Parkinson's disease: a preliminary study. Arquivos de neuro-psiquiatria, 2023, Volume: 81, Issue:5 Topics: Antiparkinson Agents; Double-Blind Method; Doxycycline; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Parkinson Disease	2023
Classification of l-DOPA pharmacokinetics shapes and creating a predictive model. Parkinsonism & related disorders, 2023, Volume: 114 Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Humans; Levodopa; Parkinson Disease	2023
Multimodal imaging study of the 5-HT NeuroImage. Clinical, 2023, Volume: 39 Topics: Animals; Dyskinesias; Fluorodeoxyglucose F18; Levodopa; Multimodal Imaging; Parkinson Disease; Rats; Receptor, Serotonin, 5-HT1A; Serotonin	2023
D2 dopamine receptors and the striatopallidal pathway modulate L-DOPA-induced dyskinesia in the mouse. Neurobiology of disease, 2023, 10-01, Volume: 186 Topics: Animals; Dopamine Agonists; Dyskinesias; Levodopa; Mice; Oxidopamine; Quinpirole; Receptors, Dopamine D2	2023
Slow wave activity across sleep-night could predict levodopa-induced dyskinesia. Scientific reports, 2023, 09-19, Volume: 13, Issue:1 Topics: Dyskinesias; Humans; Levodopa; Parkinson Disease; Sleep; Sleep, Slow-Wave	2023
Levodopa-induced dyskinesia in early-onset Parkinson's disease (EOPD) associates with glucocerebrosidase mutation: A next-generation sequencing study in EOPD patients in Thailand. PloS one, 2023, Volume: 18, Issue:10 Topics: Age of Onset; Dyskinesias; Glucosylceramidase; High-Throughput Nucleotide Sequencing; Homozygote; Humans; Levodopa; Mutation; Parkinson Disease; Sequence Deletion; Thailand	2023
Safety and tolerability of long-term apomorphine infusion in advanced Parkinson's disease: an Indian multi-center (APO-IND) experience. Scientific reports, 2023, 10-31, Volume: 13, Issue:1 Topics: Antiparkinson Agents; Apomorphine; Dopamine; Dyskinesias; Humans; Levodopa; Parkinson Disease; Quality of Life	2023
The ratio of M1 to M2 microglia in the striatum determines the severity of L-Dopa-induced dyskinesias. Journal of neurochemistry, 2023, Volume: 167, Issue:5 Topics: Animals; Anti-Inflammatory Agents; Antiparkinson Agents; Corpus Striatum; Dyskinesias; Indomethacin; Inflammation; Levodopa; Mice; Microglia; Minocycline; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley	2023
Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects. Biomolecules, 2019, 09-01, Volume: 9, Issue:9 Topics: Animals; Cyclic AMP; Dopamine; Dopaminergic Neurons; Dyskinesias; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Signal Transduction	2019
Parkinson's disease-associated dyskinesia in countries with low access to levodopa-sparing regimens. Movement disorders : official journal of the Movement Disorder Society, 2019, Volume: 34, Issue:12 Topics: Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Parkinson Disease	2019
Determinants of Low Body Mass Index in Patients with Parkinson's Disease: A Multicenter Case-Control Study. Journal of Parkinson's disease, 2020, Volume: 10, Issue:1 Topics: Aged; Body Mass Index; Case-Control Studies; Constipation; Deglutition Disorders; Dopamine Agents; Dyskinesias; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index	2020
Cardiac Noradrenaline Turnover and Heat Shock Protein 27 Phosphorylation in Dyskinetic Monkeys. Movement disorders : official journal of the Movement Disorder Society, 2020, Volume: 35, Issue:4 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dyskinesias; HSP27 Heat-Shock Proteins; Levodopa; Macaca fascicularis; Male; Norepinephrine; Phosphorylation; Tyrosine 3-Monooxygenase	2020
[Current Status and Future Prospects of Therapeutic Development of Parkinson's Disease]. Brain and nerve = Shinkei kenkyu no shinpo, 2020, Volume: 72, Issue:1 Topics: alpha-Synuclein; Disease Progression; Dyskinesias; Humans; Levodopa; Parkinson Disease	2020
Integrated transcriptome expression profiling reveals a novel lncRNA associated with L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Aging, 2020, 01-10, Volume: 12, Issue:1 Topics: Animals; Antiparkinson Agents; Biomarkers; Computational Biology; Disease Models, Animal; Dyskinesias; Gene Expression Profiling; Gene Regulatory Networks; Immunohistochemistry; Levodopa; Models, Biological; Parkinson Disease; Rats; RNA, Long Noncoding; Transcriptome	2020
Aromatic L-Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society, 2020, Volume: 35, Issue:5 Topics: Antiparkinson Agents; Dyskinesias; Genetic Therapy; Humans; Levodopa; Parkinson Disease	2020
Self-assembled polydopamine nanoparticles improve treatment in Parkinson's disease model mice and suppress dopamine-induced dyskinesia. Acta biomaterialia, 2020, Volume: 109 Topics: Animals; Cattle; Cell Line; Disease Models, Animal; Dopamine; Dyskinesias; Indoles; Levodopa; Male; Mice, Inbred C57BL; Mice, Inbred ICR; Nanoparticles; Parkinson Disease; Polymers	2020
Impulse Control Disorders and Levodopa-Induced Dyskinesias in Parkinson's Disease: Pulsatile versus Continuous Dopaminergic Stimulation. Journal of Parkinson's disease, 2020, Volume: 10, Issue:3 Topics: Aged; Aged, 80 and over; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agents; Dyskinesias; Female; Humans; Impulsive Behavior; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Severity of Illness Index; Surveys and Questionnaires	2020
Initial motor reserve and long-term prognosis in Parkinson's disease. Neurobiology of aging, 2020, Volume: 92 Topics: Aged; Corpus Striatum; Disease Progression; Dopamine; Dyskinesias; Female; Gait Disorders, Neurologic; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Parkinson Disease; Prognosis; Time Factors	2020
Predicting levodopa-induced dyskinesia. Arquivos de neuro-psiquiatria, 2020, Volume: 78, Issue:4 Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Parkinson Disease	2020
Reply to: Letter to Editor by Chaudhuri, Jenner, Antonini. Movement disorders : official journal of the Movement Disorder Society, 2020, Volume: 35, Issue:5 Topics: Dyskinesias; Humans; Levodopa; Parkinson Disease	2020
[New Therapeutic Options for the Individualised Titration of Levodopa]. Fortschritte der Neurologie-Psychiatrie, 2021, Volume: 89, Issue:1-02 Topics: Antiparkinson Agents; Carbidopa; Dyskinesias; Humans; Levodopa; Parkinson Disease	2021
Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia. Journal of Parkinson's disease, 2020, Volume: 10, Issue:3 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Capsules; Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease	2020
µ Opioid Receptor Agonism for L-DOPA-Induced Dyskinesia in Parkinson's Disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2020, 08-26, Volume: 40, Issue:35 Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Dyskinesias; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Female; Humans; Levodopa; Macaca fascicularis; MPTP Poisoning; Neurotransmitter Agents; Receptors, Opioid, mu	2020
Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients Turkish journal of medical sciences, 2021, 02-26, Volume: 51, Issue:1 Topics: Abdomen, Acute; Aged; Carbidopa; Catheterization; Deglutition Disorders; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Dysarthria; Dyskinesias; Endoscopy; Female; Gait; Gels; Humans; Intestines; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome; Turkey	2021
Optimizing Individualized Treatment Planning for Parkinson's Disease Using Deep Reinforcement Learning. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2020, Volume: 2020 Topics: Clinical Decision-Making; Dyskinesias; Humans; Levodopa; Parkinson Disease	2020
Dyskinesia Severity Estimation in Patients with Parkinson's Disease Using Wearable Sensors and A Deep LSTM Network. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2020, Volume: 2020 Topics: Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Parkinson Disease; Wearable Electronic Devices	2020
The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson's Disease. Cells, 2020, 10-09, Volume: 9, Issue:10 Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Gene Expression Regulation; Levodopa; Male; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Vilazodone Hydrochloride	2020
A man in his fifties with increasing motor fluctuations, sleep impairment and altered mental status. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2020, 10-13, Volume: 140, Issue:14 Topics: Antiparkinson Agents; Dyskinesias; Electroconvulsive Therapy; Humans; Levodopa; Male; Mental Disorders; Parkinson Disease; Sleep	2020
Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia. Movement disorders : official journal of the Movement Disorder Society, 2021, Volume: 36, Issue:2 Topics: Dopamine; Dyskinesias; Humans; Levodopa; Parkinson Disease; Positron-Emission Tomography; Putamen	2021
Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study. Molecular biology reports, 2020, Volume: 47, Issue:11 Topics: Catechol O-Methyltransferase; Cohort Studies; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Female; Genotype; Humans; Kaplan-Meier Estimate; Levodopa; Male; Parkinson Disease; Pharmacogenetics; Polymorphism, Single Nucleotide; Receptors, Dopamine D1; Receptors, Dopamine D2	2020
The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats. Neurobiology of disease, 2021, Volume: 148 Topics: Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Cell Transplantation; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Dyskinesias; Embryo, Mammalian; Gene Knock-In Techniques; Levodopa; Mesencephalon; Oxidopamine; Parkinson Disease, Secondary; Rats; Sympatholytics; Vesicular Glutamate Transport Protein 2	2021
Dyskinesia is Closely Associated with Synchronization of Theta Oscillatory Activity Between the Substantia Nigra Pars Reticulata and Motor Cortex in the Off L-dopa State in Rats. Neuroscience bulletin, 2021, Volume: 37, Issue:3 Topics: Aged; Animals; Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Motor Cortex; Oxidopamine; Pars Reticulata; Rats; Substantia Nigra	2021
Effects of pedunculopontine nucleus cholinergic lesion on gait and dyskinesia in hemiparkinsonian rats. The European journal of neuroscience, 2021, Volume: 53, Issue:8 Topics: Animals; Cholinergic Agents; Disease Models, Animal; Dyskinesias; Gait; Gait Disorders, Neurologic; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley	2021
β‑Lapachone ameliorates L‑DOPA‑induced dyskinesia in a 6‑OHDA‑induced mouse model of Parkinson's disease. Molecular medicine reports, 2021, Volume: 23, Issue:3 Topics: Animals; Dyskinesias; Levodopa; Male; Mice; Naphthoquinones; Oxidopamine; Parkinson Disease, Secondary	2021
Blood-brain barrier permeability in Parkinson's disease patients with and without dyskinesia. Journal of neurology, 2021, Volume: 268, Issue:6 Topics: Antiparkinson Agents; Blood-Brain Barrier; Dyskinesias; Humans; Levodopa; Parkinson Disease; Permeability	2021
Early-Onset Parkinsonism and Early-Onset Parkinson's Disease: A Population-Based Study (2010-2015). Journal of Parkinson's disease, 2021, Volume: 11, Issue:3 Topics: Adult; Age of Onset; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders	2021
Temporalis Muscle Thickness as an Indicator of Sarcopenia Is Associated With Long-term Motor Outcomes in Parkinson's Disease. The journals of gerontology. Series A, Biological sciences and medical sciences, 2021, 11-15, Volume: 76, Issue:12 Topics: Antiparkinson Agents; Body Weight; Dyskinesias; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Muscle, Skeletal; Parkinson Disease; Sarcopenia	2021
Levodopa-Induced Dyskinesia in Parkinson Disease Specifically Associates With Dopaminergic Depletion in Sensorimotor-Related Functional Subregions of the Striatum. Clinical nuclear medicine, 2021, 06-01, Volume: 46, Issue:6 Topics: Aged; Cohort Studies; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Neostriatum; Parkinson Disease; Prognosis; Retrospective Studies; Sensorimotor Cortex; Tomography, Emission-Computed, Single-Photon	2021
[Progressive supranuclear paralysis with levodopa-induced dyskinesia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2021, Volume: 121, Issue:3 Topics: Aged; Dyskinesias; Humans; Levodopa; Movement Disorders; Neurodegenerative Diseases; Supranuclear Palsy, Progressive	2021
[Optimal dose of levodopa-carbidopa intestinal gel in the treatment of diphasic dyskinesia and freezing of gait]. Rinsho shinkeigaku = Clinical neurology, 2021, Jun-29, Volume: 61, Issue:6 Topics: Activities of Daily Living; Carbidopa; Dyskinesias; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Middle Aged; Parkinson Disease	2021
Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats. Frontiers in immunology, 2021, Volume: 12 Topics: Animals; Biomarkers; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dyskinesias; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Resveratrol; Substantia Nigra	2021
A method for measuring time spent in bradykinesia and dyskinesia in people with Parkinson's disease using an ambulatory monitor. Journal of neuroengineering and rehabilitation, 2021, 07-16, Volume: 18, Issue:1 Topics: Algorithms; Antiparkinson Agents; Dyskinesias; Humans; Hypokinesia; Levodopa; Parkinson Disease	2021
Assessment of striatal & postural deformities in patients with Parkinson's disease. The Indian journal of medical research, 2016, Volume: 144, Issue:5 Topics: Adult; Aged; Corpus Striatum; Dyskinesias; Female; Hand; Humans; Levodopa; Male; Middle Aged; Muscular Atrophy, Spinal; Parkinson Disease; Posture; Scoliosis; Spinal Curvatures; Tertiary Care Centers	2016
Continuous Assessment of Levodopa Response in Parkinson's Disease Using Wearable Motion Sensors. IEEE transactions on bio-medical engineering, 2018, Volume: 65, Issue:1 Topics: Aged; Algorithms; Biomechanical Phenomena; Cohort Studies; Drug Monitoring; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; ROC Curve; Wearable Electronic Devices	2018
Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice. JAMA neurology, 2017, 06-01, Volume: 74, Issue:6 Topics: Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Parkinson Disease	2017
Association of a neuronal nitric oxide synthase gene polymorphism with levodopa-induced dyskinesia in Parkinson's disease. Nitric oxide : biology and chemistry, 2018, 04-01, Volume: 74 Topics: Adult; Aged; Antiparkinson Agents; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Nitric Oxide Synthase Type I; Parkinson Disease; Polymorphism, Single Nucleotide	2018
Extended-Release Amantadine-A Smart Pill for Treatment of Levodopa-Induced Dyskinesia but Does the Evidence Justify the Cost? JAMA neurology, 2017, 08-01, Volume: 74, Issue:8 Topics: Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Dyskinesias; Humans; Levodopa; Parkinson Disease	2017
A New Evolutionary Algorithm-Based Home Monitoring Device for Parkinson's Dyskinesia. Journal of medical systems, 2017, Sep-25, Volume: 41, Issue:11 Topics: Algorithms; Antiparkinson Agents; Dyskinesias; Home Care Services; Humans; Levodopa; Parkinson Disease; Quality of Life	2017
Effectiveness of levodopa treatment for diabetic chorea with reduced striatal accumulation in dopamine transporter SPECT: a case report. Rinsho shinkeigaku = Clinical neurology, 2017, 10-27, Volume: 57, Issue:10 Topics: Aged; Amines; Chorea; Corpus Striatum; Cyclohexanecarboxylic Acids; Diabetes Complications; Dopamine Plasma Membrane Transport Proteins; Drug Therapy, Combination; Dyskinesias; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Hyperglycemic Hyperosmolar Nonketotic Coma; Levodopa; Tomography, Emission-Computed, Single-Photon; Treatment Outcome	2017
Increased putamen hypercapnic vasoreactivity in levodopa-induced dyskinesia. JCI insight, 2017, 10-19, Volume: 2, Issue:20 Topics: Aged; Antiparkinson Agents; Cerebrovascular Circulation; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Hypercapnia; Levodopa; Male; Middle Aged; Neuroimaging; Parkinson Disease; Putamen; Sensorimotor Cortex	2017
Altered mGluR5 binding potential and glutamine concentration in the 6-OHDA rat model of acute Parkinson's disease and levodopa-induced dyskinesia. Neurobiology of aging, 2018, Volume: 61 Topics: Acute Disease; Animals; Cerebral Cortex; Disease Models, Animal; Dyskinesias; Female; Glutamine; Levodopa; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Proton Magnetic Resonance Spectroscopy; Putamen; Rats, Wistar; Receptor, Metabotropic Glutamate 5	2018
Patient-driven N-of-1 in Parkinson's Disease. Lessons Learned from a Placebo-controlled Study of the Effect of Nicotine on Dyskinesia. Methods of information in medicine, 2017, Oct-24, Volume: 56, Issue:99 Topics: Dyskinesias; Female; Humans; Levodopa; Middle Aged; Nicotine; Parkinson Disease; Placebos	2017
Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease. European journal of nuclear medicine and molecular imaging, 2018, Volume: 45, Issue:3 Topics: Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron Emission Tomography Computed Tomography; Prognosis; Synapses; Time Factors; Tropanes	2018
ADS 5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia-Reply. JAMA neurology, 2017, 12-01, Volume: 74, Issue:12 Topics: Amantadine; Antiparkinson Agents; Dyskinesias; Humans; Levodopa	2017
ADS-5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia. JAMA neurology, 2017, 12-01, Volume: 74, Issue:12 Topics: Amantadine; Antiparkinson Agents; Dyskinesias; Humans; Levodopa	2017
[Symptoms and Pathophysiology of Dyskinesias]. Brain and nerve = Shinkei kenkyu no shinpo, 2017, Volume: 69, Issue:12 Topics: Dyskinesias; Humans; Levodopa; Risk Factors	2017
Serum sodium and chloride are inversely associated with dyskinesia in Parkinson's disease patients. Brain and behavior, 2017, Volume: 7, Issue:12 Topics: Age of Onset; Aged; Antiparkinson Agents; Chlorides; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Sodium; Time Factors	2017
Neurophysiological effects in cortico-basal ganglia-thalamic circuits of antidyskinetic treatment with 5-HT Experimental neurology, 2018, Volume: 302 Topics: Animals; Basal Ganglia; Brain Waves; Cerebral Cortex; Disease Models, Animal; Dyskinesias; Electric Stimulation; Evoked Potentials; Female; Levodopa; Neural Pathways; Parkinson Disease, Secondary; Piperazines; Piperidines; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Thalamus	2018
Levodopa Effect and Motor Function in Late Stage Parkinson's Disease. Journal of Parkinson's disease, 2018, Volume: 8, Issue:1 Topics: Accelerometry; Aged; Aged, 80 and over; Antidepressive Agents; Antiparkinson Agents; Depression; Disorders of Excessive Somnolence; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesias; Female; Humans; Levodopa; Male; Motor Activity; Parkinson Disease; Psychotropic Drugs; Severity of Illness Index; Sweden	2018
MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease. Journal of clinical pharmacology, 2018, Volume: 58, Issue:7 Topics: Adult; Aged; Antiparkinson Agents; Biological Availability; Brazil; Catechol O-Methyltransferase; Dopamine; Dose-Response Relationship, Drug; Dyskinesias; Female; Genotype; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Retrospective Studies; Sex Characteristics; Surveys and Questionnaires	2018
Diametric neural ensemble dynamics in parkinsonian and dyskinetic states. Nature, 2018, Volume: 557, Issue:7704 Topics: Animals; Calcium Signaling; Dopamine; Dyskinesias; Female; Levodopa; Male; Mice; Models, Biological; Movement; Neostriatum; Neurons; Parkinsonian Disorders; Receptors, Dopamine D1; Receptors, Dopamine D2	2018
The treatment of levodopa-induced dyskinesias: Surfing the serotoninergic wave. Movement disorders : official journal of the Movement Disorder Society, 2018, Volume: 33, Issue:11 Topics: Animals; Dyskinesia, Drug-Induced; Dyskinesias; Levodopa; Rats; Serotonin; Vilazodone Hydrochloride	2018
Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry. Neurodegenerative disease management, 2019, Volume: 9, Issue:1 Topics: Aged; Carbidopa; Dopamine Agents; Drug Combinations; Dyskinesias; Female; Gels; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life; Registries	2019
Changes in Dendritic Spine Density and Inhibitory Perisomatic Connectivity onto Medium Spiny Neurons in L-Dopa-Induced Dyskinesia. Molecular neurobiology, 2019, Volume: 56, Issue:9 Topics: Animals; Corpus Striatum; Cytoskeletal Proteins; Dendritic Spines; Dyskinesias; Female; Interneurons; Levodopa; Mice, Inbred C57BL; Mice, Transgenic; Nerve Net; Nerve Tissue Proteins; Oxidopamine; Parvalbumins; Plant Lectins; Proto-Oncogene Proteins c-fos; Receptors, N-Acetylglucosamine	2019
[Therapeutic and pharmacologic perspectives in Parkinson's disease]. La Revue du praticien, 2018, Volume: 68, Issue:5 Topics: Antiparkinson Agents; Disease Progression; Dyskinesias; Humans; Levodopa; Parkinson Disease	2018
Methods to Investigate the Role of β-Arrestin Signaling in Parkinson's Disease. Methods in molecular biology (Clifton, N.J.), 2019, Volume: 1957 Topics: Animals; beta-Arrestins; Disease Models, Animal; Dopamine; Dyskinesias; Humans; Levodopa; Locomotion; Mice, Knockout; Molecular Biology; Parkinson Disease; Signal Transduction; Stereotaxic Techniques	2019
Clinical correlates of repetitive speech disorders in Parkinson's disease. Journal of the neurological sciences, 2019, Jun-15, Volume: 401 Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cognition; Dyskinesias; Female; Humans; Levodopa; Male; Memory; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Sex Factors; Speech Disorders; Speech Production Measurement; Stroop Test; Verbal Behavior	2019
Measurement of serum cystatin C: A valuable tool for evaluating dyskinesia in Parkinson's disease. Neuroscience letters, 2019, 07-13, Volume: 705 Topics: Aged; Case-Control Studies; Cystatin C; Dyskinesias; Female; Humans; Levodopa; Male; Parkinson Disease; Predictive Value of Tests; Severity of Illness Index	2019
l-Dopa-free learned dyskinetic behavior in a Parkinson's primate model. Movement disorders : official journal of the Movement Disorder Society, 2019, Volume: 34, Issue:8 Topics: Animals; Antiparkinson Agents; Conditioning, Psychological; Disease Models, Animal; Dyskinesia, Drug-Induced; Dyskinesias; Levodopa; Macaca; Parkinsonian Disorders	2019
The Use of Data from the Parkinson's KinetiGraph to Identify Potential Candidates for Device Assisted Therapies. Sensors (Basel, Switzerland), 2019, May-15, Volume: 19, Issue:10 Topics: Aged; Algorithms; Deep Brain Stimulation; Dyskinesias; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Sensitivity and Specificity; Tremor	2019
Neurostimulation earlier for selected adults with Parkinson's disease. BMJ (Clinical research ed.), 2013, Feb-20, Volume: 346 Topics: Antiparkinson Agents; Deep Brain Stimulation; Dyskinesias; Humans; Levodopa; Middle Aged; Parkinson Disease; Patient Selection; Quality of Life; Treatment Outcome	2013
Possible mechanisms involved in subthalamotomy-induced dyskinesia in patients with Parkinson's disease. Stereotactic and functional neurosurgery, 2013, Volume: 91, Issue:5 Topics: Adult; Aged; Antiparkinson Agents; Dyskinesias; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Retrospective Studies; Subthalamic Nucleus; Subthalamus	2013
Automated assessment of bradykinesia and dyskinesia in Parkinson's disease. Journal of Parkinson's disease, 2012, Volume: 2, Issue:1 Topics: Adult; Algorithms; Antiparkinson Agents; Case-Control Studies; Dyskinesias; Electronic Data Processing; Female; Humans; Hypokinesia; Levodopa; Male; Parkinson Disease; Spectrum Analysis; Time Factors	2012
Novel GCH-1 mutations and unusual long-lasting dyskinesias in Korean families with dopa-responsive dystonia. Parkinsonism & related disorders, 2013, Volume: 19, Issue:12 Topics: Adolescent; Adult; Age of Onset; Asian People; Child; Child, Preschool; Dopamine Agents; Dyskinesias; Dystonic Disorders; Family; Female; GTP Cyclohydrolase; Humans; Infant; Levodopa; Male; Middle Aged; Mutation; Pedigree; Phenylketonurias; Young Adult	2013
Proteomic analysis of striatum from MPTP-treated marmosets (Callithrix jacchus) with L-DOPA-induced dyskinesia of differing severity. Journal of molecular neuroscience : MN, 2014, Volume: 52, Issue:2 Topics: Animals; Callithrix; Dyskinesias; Levodopa; MPTP Poisoning; Neostriatum; Proteome	2014
Gait and upper limb variability in Parkinson's disease patients with and without freezing of gait. Journal of neurology, 2014, Volume: 261, Issue:2 Topics: Aged; Antiparkinson Agents; Data Interpretation, Statistical; Dyskinesias; Female; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Movement; Neurologic Examination; Parkinson Disease; Surveys and Questionnaires; Upper Extremity	2014
Occlusal treatment with bite splint improves dyskinesia in Parkinson's disease patient: a case report. The Bulletin of Tokyo Dental College, 2013, Volume: 54, Issue:3 Topics: Activities of Daily Living; Antiparkinson Agents; Bromocriptine; Cabergoline; Clonidine; Dyskinesias; Ergolines; Female; Hand Strength; Humans; Levodopa; Middle Aged; Motor Skills; Occlusal Splints; Parkinson Disease; Posture	2013
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum. Scientific reports, 2014, Jan-16, Volume: 4 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Combinations; Dyskinesias; Female; Levodopa; Macaca mulatta; Male; Parkinson Disease	2014
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease. Neuroscience, 2014, Apr-18, Volume: 265 Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Excitatory Amino Acid Antagonists; Levodopa; Male; Memantine; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley	2014
A conditioned response as a measure of impulsive-compulsive behaviours in Parkinson's disease. PloS one, 2014, Volume: 9, Issue:2 Topics: Aged; Anxiety; Apathy; Compulsive Behavior; Conditioning, Psychological; Depression; Disruptive, Impulse Control, and Conduct Disorders; Dyskinesias; Humans; Hypokinesia; Impulsive Behavior; Levodopa; Middle Aged; Parkinson Disease; Weights and Measures	2014
Adenosine A₂A-receptor antagonist istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosets. Journal of pharmacological sciences, 2014, Volume: 124, Issue:4 Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Callithrix; Drug Synergism; Dyskinesias; Female; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Purines	2014
The H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned rats. European journal of pharmacology, 2014, Oct-15, Volume: 741 Topics: Animals; Dyskinesia, Drug-Induced; Dyskinesias; Histamine Agonists; Imidazoles; Levodopa; Male; Oxidopamine; Piperidines; Rats; Rats, Wistar	2014
Motion sensor dyskinesia assessment during activities of daily living. Journal of Parkinson's disease, 2014, Volume: 4, Issue:4 Topics: Activities of Daily Living; Adult; Aged; Algorithms; Antiparkinson Agents; Dyskinesias; Female; Hand; Humans; Levodopa; Male; Middle Aged; Motion Perception; Movement; Parkinson Disease; Severity of Illness Index	2014
Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats. Scientific reports, 2014, Oct-29, Volume: 4 Topics: Amino Acid Motifs; Animals; Binding Sites; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpus Striatum; Disease Models, Animal; Dyskinesias; Female; Levodopa; Neurons; Oxidopamine; Parkinson Disease; Protein Binding; Protein Interaction Domains and Motifs; Rats; Receptors, Dopamine D2	2014
Does idiopathic restless legs syndrome delay onset and reduce severity of Parkinson's disease: a pilot study. The International journal of neuroscience, 2015, Volume: 125, Issue:7 Topics: Age Factors; Aged; Antiparkinson Agents; Disease Progression; Dyskinesias; Female; Humans; Levodopa; Logistic Models; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Pilot Projects; Restless Legs Syndrome; Severity of Illness Index	2015
Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats. Scientific reports, 2014, Dec-16, Volume: 4 Topics: Adrenergic Agents; Animals; Benserazide; Blotting, Western; Corpus Striatum; Cyclic AMP-Dependent Protein Kinases; Dopamine Agents; Drug Combinations; Dyskinesias; Female; Fluorescent Antibody Technique; Lactic Acid; Levodopa; Microspheres; Neurons; Oxidopamine; Parkinson Disease; Phosphoproteins; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; tau Proteins; Transcription Factors	2014
The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study. Neurobiology of aging, 2015, Volume: 36, Issue:4 Topics: Aged; Dopamine; Dyskinesias; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Protein Binding; Serotonergic Neurons; Serotonin; Serotonin Plasma Membrane Transport Proteins; Severity of Illness Index; Synapses	2015
Fluctuating Cotard syndrome in a patient with advanced Parkinson disease. The neurologist, 2015, Volume: 19, Issue:3 Topics: Aged; Antiparkinson Agents; Delusions; Dyskinesias; Female; Humans; Levodopa; Parkinson Disease	2015
Varying time-course of effects of high frequency stimulation of sub-regions of the globus pallidus in patients with parkinson's disease. Parkinsonism & related disorders, 2015, Volume: 21, Issue:6 Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Dyskinesias; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Time Factors; Treatment Outcome; Tremor	2015
Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2015, May-12, Volume: 112, Issue:19 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arrestins; Behavior, Animal; beta-Arrestins; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Gene Deletion; Levodopa; Macaca; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Signal Transduction; Up-Regulation	2015
Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry. Parkinsonism & related disorders, 2015, Volume: 21, Issue:8 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Duodenum; Dyskinesia, Drug-Induced; Dyskinesias; Female; Follow-Up Studies; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Registries; Spain; Treatment Outcome	2015
GRK3 suppresses L-DOPA-induced dyskinesia in the rat model of Parkinson's disease via its RGS homology domain. Scientific reports, 2015, Jun-04, Volume: 5 Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dyskinesias; G-Protein-Coupled Receptor Kinase 3; Gene Expression; Gene Knockdown Techniques; Levodopa; Parkinson Disease; Protein Interaction Domains and Motifs; Rats; RGS Proteins; RNA Interference; RNA, Small Interfering; Signal Transduction	2015
Improvement of dyskinesias with L-dopa infusion in advanced Parkinson's disease. Acta neurologica Scandinavica, 2016, Volume: 133, Issue:6 Topics: Aged; Antiparkinson Agents; Carbidopa; Dyskinesias; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Quality of Life	2016
Risk and course of motor complications in a population-based incident Parkinson's disease cohort. Parkinsonism & related disorders, 2016, Volume: 22 Topics: Age Factors; Aged; Antiparkinson Agents; Cohort Studies; Disease Progression; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Incidence; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Movement Disorders; Norway; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Risk Factors; Sex Factors; Superior Sagittal Sinus	2016
p11 modulates L-DOPA therapeutic effects and dyskinesia via distinct cell types in experimental Parkinsonism. Proceedings of the National Academy of Sciences of the United States of America, 2016, Feb-02, Volume: 113, Issue:5 Topics: Animals; Annexin A2; Dyskinesias; Levodopa; Mice; Mice, Knockout; Parkinsonian Disorders; S100 Proteins	2016
Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-parkinsonian rats. Pharmacology, biochemistry, and behavior, 2016, Volume: 142 Topics: Animals; Antidepressive Agents, Tricyclic; Corpus Striatum; Dopamine; Dyskinesias; Levodopa; Male; Norepinephrine Plasma Membrane Transport Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin Plasma Membrane Transport Proteins	2016
Dopaminergic-induced dyskinesia assessment based on a single belt-worn accelerometer. Artificial intelligence in medicine, 2016, Volume: 67 Topics: Accelerometry; Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Monitoring, Physiologic; Parkinson Disease; Support Vector Machine	2016
LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias. Molecular brain, 2016, 05-11, Volume: 9, Issue:1 Topics: Animals; Disease Models, Animal; Dyskinesias; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Phosphorylation; Protein Kinase Inhibitors; Rats, Sprague-Dawley	2016
Weight loss and decubitus duodenal ulcer in Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion. Journal of neural transmission (Vienna, Austria : 1996), 2016, Volume: 123, Issue:12 Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenal Ulcer; Duodenum; Dyskinesias; Endoscopes, Gastrointestinal; Humans; Levodopa; Male; Parkinson Disease; Tomography, X-Ray Computed; Weight Loss	2016
Determination of dopamine, serotonin, biosynthesis precursors and metabolites in rat brain microdialysates by ultrasonic-assisted in situ derivatization-dispersive liquid-liquid microextraction coupled with UHPLC-MS/MS. Talanta, 2016, Dec-01, Volume: 161 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Brain Chemistry; Chromatography, High Pressure Liquid; Dopamine; Dyskinesias; Epinephrine; Hydroxyindoleacetic Acid; Levodopa; Liquid Phase Microextraction; Male; Norepinephrine; Rats, Sprague-Dawley; Rhodamines; Serotonin; Tandem Mass Spectrometry; Tryptophan; Ultrasonics	2016
Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa-Induced Dyskinesia in Parkinson's Disease. International journal of molecular sciences, 2017, Jan-24, Volume: 18, Issue:2 Topics: Aged; Alleles; Animals; Disease Progression; Dyskinesias; Female; Genetic Predisposition to Disease; Genotype; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Receptors, Dopamine	2017
Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice. Movement disorders : official journal of the Movement Disorder Society, 2017, Volume: 32, Issue:4 Topics: Animals; Antiparkinson Agents; Channelrhodopsins; Cocaine; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Female; Gene Expression Regulation; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Oxidopamine; Parkinsonian Disorders; Receptors, Dopamine D1; Sympatholytics	2017
Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease. Movement disorders : official journal of the Movement Disorder Society, 2017, Volume: 32, Issue:4 Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain; Channelrhodopsins; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesias; Functional Laterality; Levodopa; Male; Optogenetics; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Transduction, Genetic; Tyrosine 3-Monooxygenase	2017
Differential effects of gaseous versus injectable anesthetics on changes in regional cerebral blood flow and metabolism induced by l-DOPA in a rat model of Parkinson's disease. Experimental neurology, 2017, Volume: 292 Topics: Anesthetics; Animals; Basal Ganglia; Cerebrovascular Circulation; Dyskinesia, Drug-Induced; Dyskinesias; Gases; Isoflurane; Ketamine; Levodopa; Parkinson Disease; Rats	2017
Inversion of dopamine responses in striatal medium spiny neurons and involuntary movements. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2008, Jul-23, Volume: 28, Issue:30 Topics: Action Potentials; Analysis of Variance; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Female; Levodopa; Macaca mulatta; Neurons; Parkinsonian Disorders	2008
The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors. Neurobiology of disease, 2008, Volume: 32, Issue:2 Topics: Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesias; Histocompatibility Antigens Class II; Levodopa; Male; Microscopy, Electron, Transmission; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Synapses; Tissue Transplantation; Tyrosine 3-Monooxygenase	2008
Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease. Neurobiology of disease, 2008, Volume: 32, Issue:2 Topics: Adrenergic Agents; Amphetamine; Analgesics, Non-Narcotic; Analysis of Variance; Animals; Antiparkinson Agents; Brain Tissue Transplantation; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Dyskinesias; Embryo, Mammalian; Encephalitis; Female; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Levodopa; Mesencephalon; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rats, Wistar; Skin Transplantation	2008
Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias. Journal of molecular neuroscience : MN, 2009, Volume: 38, Issue:2 Topics: Animals; Autoradiography; Behavior, Animal; Benserazide; Benzoxazoles; Cabergoline; Corpus Striatum; Dopamine Agents; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Ergolines; Female; Humans; Levodopa; Macaca fascicularis; MPTP Poisoning; Ovariectomy; Piperidines; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate	2009
L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease. Neurobiology of aging, 2010, Volume: 31, Issue:6 Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antiparkinson Agents; Antipsychotic Agents; Benzazepines; Berberine; CHO Cells; Corpus Striatum; Cricetinae; Cricetulus; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Drug Interactions; Dyskinesias; Gene Expression Regulation; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; RNA, Messenger; Serotonin Receptor Agonists; Transfection; Tritium	2010
[Motor fluctuations and dyskinesias in Parkinson's disease: variables that discriminate both complications in a sample of 285 patients]. Neurologia (Barcelona, Spain), 2008, Volume: 23, Issue:8 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cross-Sectional Studies; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Survival Rate	2008
[Effects of traditional Chinese herbal medicine on the neurobehavioral manifestations and the activity of dopamine D2 receptor in corpora striatum of rats with levodopa-induced dyskinesias]. Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine, 2008, Volume: 6, Issue:10 Topics: Animals; Benserazide; Corpus Striatum; Drugs, Chinese Herbal; Dyskinesias; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Phytotherapy; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2	2008
Dyskinesia-induced postural instability in Parkinson's disease. Parkinsonism & related disorders, 2009, Volume: 15, Issue:5 Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Body Weight; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Postural Balance; Posture	2009
Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2. Neurochemistry international, 2009, Volume: 54, Issue:1 Topics: Amphetamine; Animals; Benzoxazines; Calcium Channel Blockers; Cannabinoids; Corpus Striatum; Dopamine; Dyskinesias; Glutamine; Homovanillic Acid; Levodopa; Male; Morpholines; Naphthalenes; Oxidopamine; Rats; Rats, Wistar	2009
Transient disabling dyskinesias: a predictor of good outcome in subthalamic nucleus deep brain stimulation in Parkinson's disease. European neurology, 2009, Volume: 61, Issue:2 Topics: Adult; Antiparkinson Agents; Brain; Deep Brain Stimulation; Dyskinesias; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease; Radiography; Retrospective Studies; Subthalamic Nucleus; Treatment Outcome	2009
L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. Journal of neurochemistry, 2009, Volume: 108, Issue:3 Topics: Animals; Antiparkinson Agents; Blotting, Western; Dyskinesias; Extracellular Signal-Regulated MAP Kinases; Fluorescent Antibody Technique; Histones; Levodopa; Male; Mice; Mice, Inbred C57BL; Neostriatum; Neurons; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Receptors, Dopamine D1; Receptors, Dopamine D2; Ribosomal Protein S6 Kinases, 90-kDa; Signal Transduction; Substantia Nigra; Sympatholytics	2009
Therapeutic efficacy of unilateral subthalamotomy in Parkinson's disease: results in 89 patients followed for up to 36 months. Journal of neurology, neurosurgery, and psychiatry, 2009, Volume: 80, Issue:9 Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Cognition; Drug Resistance; Dyskinesias; Female; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Stereotaxic Techniques; Subthalamic Nucleus; Treatment Outcome	2009
Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease. Neurobiology of disease, 2009, Volume: 35, Issue:1 Topics: 5,7-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine Uptake Inhibitors; Dyskinesias; Embryo, Mammalian; Female; Levodopa; Mesencephalon; Oxidopamine; Parkinson Disease; Pregnancy; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Agents; Transplants; Tyrosine 3-Monooxygenase	2009
Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias. European journal of neurology, 2009, Volume: 16, Issue:8 Topics: Age of Onset; Aged; Antiparkinson Agents; Body Mass Index; Body Weight; Dopamine Agents; Dyskinesias; Eating; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Severity of Illness Index; Time Factors; Weight Loss	2009
[Treatment of early Parkinson's disease]. Revue medicale de Liege, 2009, Volume: 64, Issue:4 Topics: Adrenergic beta-Antagonists; Antiparkinson Agents; Benzodiazepines; Cholinergic Antagonists; Dopamine Agonists; Drug Therapy, Combination; Dyskinesias; Early Diagnosis; Humans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Prognosis; Quality of Life; Treatment Outcome	2009
[Systematic evaluation on influence of dopaminergic therapy: on motor complications in Parkinson's disease]. Zhonghua yi xue za zhi, 2009, Feb-24, Volume: 89, Issue:7 Topics: Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome	2009
Is there a difference in gastric emptying between Parkinson's disease patients under long-term L-dopa therapy with and without motor fluctuations? An analysis using the 13C-acetate breath test. Journal of neurology, 2009, Volume: 256, Issue:12 Topics: Acetates; Adult; Aged; Aged, 80 and over; Carbon Isotopes; Dopamine Agents; Dyskinesias; Female; Gastric Emptying; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Parkinson Disease	2009
Does subthalamotomy have a place in the treatment of Parkinson's disease? Journal of neurology, neurosurgery, and psychiatry, 2009, Volume: 80, Issue:9 Topics: Antiparkinson Agents; Drug Resistance; Dyskinesias; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Postoperative Complications; Subthalamic Nucleus	2009
TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease. European journal of pharmacology, 2009, Oct-12, Volume: 620, Issue:1-3 Topics: Amantadine; Animals; Behavior, Animal; Disease Models, Animal; Dyskinesias; Extracellular Space; Levodopa; Male; Microdialysis; Morphinans; Neostriatum; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Rotation; Spiro Compounds; Time Factors	2009
Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats. The European journal of neuroscience, 2009, Volume: 30, Issue:5 Topics: Animals; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dynorphins; Dyskinesias; Electron Transport Complex IV; Enkephalins; Glutamate Decarboxylase; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Subthalamic Nucleus	2009
Pain in Parkinson's disease. Arquivos de neuro-psiquiatria, 2009, Volume: 67, Issue:3A Topics: Antiparkinson Agents; Depression; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Pain; Pain Measurement; Parkinson Disease; Prospective Studies	2009
Levodopa-induced dyskinesias detection based on the complexity of involuntary movements. Journal of neuroscience methods, 2010, Jan-30, Volume: 186, Issue:1 Topics: Aged; Antiparkinson Agents; Biological Clocks; Biomechanical Phenomena; Brain; Cognition; Diagnosis, Differential; Dyskinesia, Drug-Induced; Dyskinesias; Entropy; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Neural Networks, Computer; Neuropsychological Tests; Predictive Value of Tests; Signal Processing, Computer-Assisted; Time Factors	2010
The FRAGAMP study: environmental and genetic factors in Parkinson's disease, methods and clinical features. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2010, Volume: 31, Issue:1 Topics: Aged; Antiparkinson Agents; Case-Control Studies; Dopamine Agonists; Dyskinesias; Environment; Female; Genetic Predisposition to Disease; Geography; Humans; Italy; Levodopa; Male; Middle Aged; Parkinson Disease; Sequence Analysis, DNA; Severity of Illness Index; Spouses; Surveys and Questionnaires	2010
Large differences in levodopa dose requirement in Parkinson's disease: men use higher doses than women. European journal of neurology, 2010, Volume: 17, Issue:2 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Registries; Sex Factors; Sweden; Time Factors	2010
Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats. The European journal of neuroscience, 2010, Volume: 31, Issue:3 Topics: Animals; Antiparkinson Agents; Behavior, Animal; Calcium Channel Blockers; Cell Transplantation; Dendritic Spines; Disease Models, Animal; Dopamine; Dyskinesias; Female; Levodopa; Male; Neurons; Nimodipine; Parkinson Disease; Pregnancy; Rats; Rats, Sprague-Dawley; Vibrissae	2010
Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets. Movement disorders : official journal of the Movement Disorder Society, 2010, Feb-15, Volume: 25, Issue:3 Topics: Animals; Antiparkinson Agents; Benzothiazoles; Callithrix; Carbidopa; Disability Evaluation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesias; Levodopa; Male; Motor Activity; MPTP Poisoning; Pramipexole; Time Factors	2010
Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease. Brain : a journal of neurology, 2010, Volume: 133, Issue:Pt 2 Topics: Animals; Chickens; Corpus Striatum; Dependovirus; Disease Models, Animal; Dyskinesias; Female; Gene Transfer Techniques; Genetic Vectors; Humans; Levodopa; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley	2010
Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2010, Volume: 25 Suppl 1 Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Humans; Levodopa; Neurons; Parkinson Disease; Serotonin; Transplants	2010
Actigraphic evaluation of motor fluctuations in patients with Parkinson's disease. The International journal of neuroscience, 2010, Volume: 120, Issue:2 Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Monitoring, Physiologic; Motor Activity; Movement; Parkinson Disease; Posture; Wrist	2010
Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Science translational medicine, 2010, Apr-21, Volume: 2, Issue:28 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Dose-Response Relationship, Drug; Dyskinesias; Endocytosis; G-Protein-Coupled Receptor Kinases; Gene Knockdown Techniques; Genetic Therapy; Humans; Lentivirus; Levodopa; Macaca; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Rotation; Signal Transduction	2010
Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2010, May-26, Volume: 30, Issue:21 Topics: Animals; Corpus Striatum; Disease Models, Animal; Drug Administration Schedule; Dyskinesias; Functional Laterality; Gene Expression Regulation; Gene Transfer Techniques; Genetic Vectors; Green Fluorescent Proteins; Levodopa; Male; Motor Activity; Mutation; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Sympatholytics; Time Factors	2010
Movement disorders ii: chorea, dystonia, myoclonus, and tremor. Pediatrics in review, 2010, Volume: 31, Issue:7 Topics: Child; Chorea; Dopamine Agents; Dyskinesia, Drug-Induced; Dyskinesias; Dystonia; Humans; Levodopa; Lupus Erythematosus, Systemic; Myoclonus; Tremor	2010
Levodopa-induced belly dancer's dyskinesias in Parkinson's disease: report of one case. Movement disorders : official journal of the Movement Disorder Society, 2010, Aug-15, Volume: 25, Issue:11 Topics: Aged; Antiparkinson Agents; Dancing; Dyskinesias; Female; Humans; Levodopa; Parkinson Disease	2010
Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia. PloS one, 2010, Aug-23, Volume: 5, Issue:8 Topics: Animals; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesias; Extracellular Signal-Regulated MAP Kinases; Female; Levodopa; Macaca mulatta; MAP Kinase Signaling System; Parkinsonian Disorders; ras Proteins	2010
[GRK6, a new therapeutic approach to alleviate L-dopa-induced dyskinesia]. Medecine sciences : M/S, 2010, Volume: 26, Issue:10 Topics: Animals; Dyskinesias; Endocytosis; G-Protein-Coupled Receptor Kinases; Haplorhini; Humans; Levodopa	2010
Motor complications in Parkinson's disease: ten year follow-up study. Movement disorders : official journal of the Movement Disorder Society, 2010, Dec-15, Volume: 25, Issue:16 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disease Progression; Dyskinesias; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Prospective Studies; Severity of Illness Index; Statistics, Nonparametric	2010
Living with advanced Parkinson's disease: a constant struggle with unpredictability. Journal of advanced nursing, 2011, Volume: 67, Issue:2 Topics: Activities of Daily Living; Adaptation, Psychological; Adult; Aged; Attitude to Health; Chronic Disease; Deep Brain Stimulation; Disease Progression; Drug Administration Schedule; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Nursing Methodology Research; Parkinson Disease; Qualitative Research	2011
The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson's disease. Parkinsonism & related disorders, 2011, Volume: 17, Issue:1 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Body Weight; Dose-Response Relationship, Drug; Dyskinesias; Female; Humans; Levodopa; Logistic Models; Male; Middle Aged; Parkinson Disease; Prognosis	2011
[Update on current care guidelines. Parkinson's disease]. Duodecim; laaketieteellinen aikakauskirja, 2010, Volume: 126, Issue:19 Topics: Age Factors; Aged; Antiparkinson Agents; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Practice Guidelines as Topic	2010
Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice. Proceedings of the National Academy of Sciences of the United States of America, 2011, Jan-11, Volume: 108, Issue:2 Topics: Adenosine A2 Receptor Antagonists; Aminoacetonitrile; Animals; Aphakia; Choline O-Acetyltransferase; Cholinergic Fibers; Disease Models, Animal; Dopamine; Dyskinesias; Gene Expression Regulation; Homeodomain Proteins; Levodopa; Mice; Mice, Transgenic; Neurons; Parkinson Disease; Phosphorylation; Transcription Factors	2011
[Patients' perspective on Parkinson disease therapies: results of a large-scale survey in Japan]. Brain and nerve = Shinkei kenkyu no shinpo, 2011, Volume: 63, Issue:3 Topics: Aged; Antiparkinson Agents; Attitude; Dyskinesias; Female; Humans; Interviews as Topic; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Surveys and Questionnaires	2011
The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural study. PloS one, 2011, Volume: 6, Issue:9 Topics: Amphetamine; Animals; Behavior, Animal; Dyskinesias; Electrophysiology; Female; Ibotenic Acid; Levodopa; Locus Coeruleus; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley	2011
Extent of pre-operative L-DOPA-induced dyskinesia predicts the severity of graft-induced dyskinesia after fetal dopamine cell transplantation. Experimental neurology, 2011, Volume: 232, Issue:2 Topics: Amphetamines; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Dyskinesias; Female; Fetal Tissue Transplantation; Levodopa; Oxidopamine; Postoperative Complications; Predictive Value of Tests; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Substantia Nigra; Sympatholytics	2011
Imaging mass spectrometry reveals elevated nigral levels of dynorphin neuropeptides in L-DOPA-induced dyskinesia in rat model of Parkinson's disease. PloS one, 2011, Volume: 6, Issue:9 Topics: Animals; Dynorphins; Dyskinesias; Enkephalins; Female; Immunohistochemistry; Levodopa; Male; Mass Spectrometry; Mice; Mice, Knockout; Parkinson Disease; Protein Precursors; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization	2011
On automated assessment of Levodopa-induced dyskinesia in Parkinson's disease. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2011, Volume: 2011 Topics: Antiparkinson Agents; Automation; Dyskinesias; Humans; Levodopa; Parkinson Disease	2011
Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease. NeuroImage, 2012, May-15, Volume: 61, Issue:1 Topics: Algorithms; Animals; Antiparkinson Agents; Autoradiography; Basal Ganglia; Behavior, Animal; Benserazide; Blood-Brain Barrier; Capillaries; Cerebrovascular Circulation; Dyskinesias; Female; Glucose; Immunohistochemistry; Intermediate Filament Proteins; Levodopa; Nerve Tissue Proteins; Nestin; Oxidopamine; Parkinson Disease, Secondary; Permeability; Rats; Rats, Sprague-Dawley; Sympatholytics; Tyrosine 3-Monooxygenase	2012
Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat. The Journal of pharmacy and pharmacology, 2012, Volume: 64, Issue:5 Topics: Animals; Behavior, Animal; Corpus Striatum; Dopamine; Drug Synergism; Dyskinesias; Exenatide; Glucagon-Like Peptide 1; Levodopa; Lizards; Male; Oxidopamine; Parkinsonian Disorders; Peptides; Rats; Rats, Wistar; Venoms	2012
Preparation of rotigotine-loaded microspheres and their combination use with L-DOPA to modify dyskinesias in 6-OHDA-lesioned rats. Pharmaceutical research, 2012, Volume: 29, Issue:9 Topics: Animals; Dopamine Agonists; Drug Carriers; Drug Therapy, Combination; Dyskinesias; Levodopa; Male; Microspheres; Oxidopamine; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes; Thiophenes	2012
L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. The Journal of pharmacology and experimental therapeutics, 2012, Volume: 342, Issue:2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain; Drug Interactions; Dyskinesias; Female; Levodopa; Macaca; Male; Motor Activity; Parkinson Disease; Pyridines; Pyrroles; Receptors, Dopamine D4	2012
Subthalamic activity during diphasic dyskinesias in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2012, Volume: 27, Issue:9 Topics: Aged; Antiparkinson Agents; Apomorphine; Cohort Studies; Deep Brain Stimulation; Disease Progression; Dyskinesias; Electrodes, Implanted; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Subthalamic Nucleus; Theta Rhythm	2012
Impact of dopamine versus serotonin cell transplantation for the development of graft-induced dyskinesia in a rat Parkinson model. Brain research, 2012, Aug-27, Volume: 1470 Topics: Adrenergic Agents; Amphetamines; Analysis of Variance; Animals; Antiparkinson Agents; Cell Transplantation; Central Nervous System Stimulants; Disease Models, Animal; Dopaminergic Neurons; Dyskinesias; Female; Functional Laterality; Levodopa; Nerve Fibers; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; RNA-Binding Proteins; Serotonergic Neurons; Statistics as Topic; Stereotyped Behavior; Tyrosine 3-Monooxygenase	2012
Effects of L-DOPA and STN-HFS dyskinesiogenic treatments on NR2B regulation in basal ganglia in the rat model of Parkinson's disease. Neurobiology of disease, 2012, Volume: 48, Issue:3 Topics: Animals; Basal Ganglia; Deep Brain Stimulation; Dopamine Agents; Dyskinesias; Electrodes, Implanted; Immunohistochemistry; Levodopa; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Subthalamic Nucleus	2012
NMDA receptor genotypes associated with the vulnerability to develop dyskinesia. Translational psychiatry, 2012, Jan-10, Volume: 2 Topics: Age of Onset; Alleles; Antiparkinson Agents; Antipsychotic Agents; Dyskinesia, Drug-Induced; Dyskinesias; Gene Expression; Genetic Predisposition to Disease; Genotype; Humans; Huntington Disease; Levodopa; Long-Term Care; Motor Cortex; Movement Disorders; Polymorphism, Single Nucleotide; Receptors, N-Methyl-D-Aspartate; Schizophrenia	2012
Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors. The European journal of neuroscience, 2012, Volume: 36, Issue:9 Topics: Amantadine; Animals; Antiparkinson Agents; Cycloserine; Dextromethorphan; Dopamine Agents; Dyskinesias; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperazines; Pyridines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptors, N-Methyl-D-Aspartate; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists	2012
[Effects of Chinese herbal medicine Tianqi Pingchan Granule on G protein-coupled receptor kinase 6 involved in the prevention of levodopa-induced dyskinesia in rats with Parkinson disease]. Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine, 2012, Volume: 10, Issue:9 Topics: Animals; Disease Models, Animal; Drugs, Chinese Herbal; Dyskinesias; G-Protein-Coupled Receptor Kinases; Levodopa; Male; Parkinson Disease; Phytotherapy; Rats; Rats, Sprague-Dawley	2012
Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats. Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:8 Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Area Under Curve; Disease Models, Animal; Dyskinesias; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Time Factors	2013
Experimental reappraisal of continuous dopaminergic stimulation against L-dopa-induced dyskinesia. Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:8 Topics: Animals; Antiparkinson Agents; Dyskinesias; Levodopa; Male; Parkinson Disease	2013
Motor profile and drug treatment of nursing home residents with Parkinson's disease. Journal of the American Geriatrics Society, 2012, Volume: 60, Issue:12 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Dyskinesias; Female; Humans; Levodopa; Male; Nursing Homes; Parkinson Disease	2012
IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates. PloS one, 2013, Volume: 8, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antioxidants; Antiparkinson Agents; Behavior, Animal; Chromatography, High Pressure Liquid; Cyclooxygenase Inhibitors; Disease Models, Animal; Dopamine Agents; Dyskinesias; Immunohistochemistry; Levodopa; Macaca fascicularis; Magnetic Resonance Imaging; Male; Neurons; Oxidative Stress; Parkinson Disease; Positron-Emission Tomography; Thiazoles	2013
Evolution of the response to levodopa during the first 4 years of therapy. Annals of neurology, 2002, Volume: 51, Issue:6 Topics: Aged; Antiparkinson Agents; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Time Factors	2002
Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey. Neuroscience, 2002, Volume: 113, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Corpus Striatum; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Enkephalins; Female; Gene Expression Regulation; In Situ Hybridization; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Protein Precursors; RNA, Messenger; Saimiri; Substantia Nigra; Time Factors	2002
New medication recommended for Parkinson's disease. Report on medical guidelines & outcomes research, 2001, Jun-28, Volume: 12, Issue:13 Topics: Clozapine; Dibenzothiazepines; Dopamine Agonists; Dyskinesias; Hallucinations; Humans; Levodopa; Parkinson Disease; Practice Guidelines as Topic; United States	2001
Dyskinesias and grip control in Parkinson's disease are normalized by chronic stimulation of the subthalamic nucleus. Annals of neurology, 2002, Volume: 52, Issue:2 Topics: Dose-Response Relationship, Drug; Dyskinesias; Electric Stimulation Therapy; Hand Strength; Humans; Levodopa; Parkinson Disease; Reference Values; Severity of Illness Index; Subthalamic Nucleus; Time Factors	2002
Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:5 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Arousal; Callithrix; Caudate Nucleus; Corpus Striatum; Culture Techniques; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dyskinesias; Female; In Situ Hybridization; Levodopa; Locomotion; Male; Piribedil; RNA, Messenger; Severity of Illness Index; Time Factors	2002
Lesioning the thalamus for dyskinesia. Stereotactic and functional neurosurgery, 2001, Volume: 77, Issue:1-4 Topics: Antiparkinson Agents; Antipsychotic Agents; Dyskinesia, Drug-Induced; Dyskinesias; Electrocoagulation; Haloperidol; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Reoperation; Retrospective Studies; Schizophrenia; Stereotaxic Techniques; Sulpiride; Torticollis; Treatment Outcome; Tremor; Ventral Thalamic Nuclei	2001
Stereotactic subthalamic nucleus lesioning for the treatment of Parkinson's disease. Stereotactic and functional neurosurgery, 2001, Volume: 77, Issue:1-4 Topics: Antiparkinson Agents; Combined Modality Therapy; Confusion; Dysarthria; Dyskinesias; Electric Stimulation; Electrocoagulation; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Prospective Studies; Recurrence; Safety; Severity of Illness Index; Stereotaxic Techniques; Subthalamic Nucleus; Tomography, X-Ray Computed; Treatment Outcome	2001
Oscillatory local field potentials recorded from the subthalamic nucleus of the alert rat. Experimental neurology, 2002, Volume: 177, Issue:2 Topics: Animals; Antiparkinson Agents; Biological Clocks; Dopamine Agonists; Dyskinesias; Female; Humans; Levodopa; Male; Membrane Potentials; Middle Aged; Motor Activity; Parkinson Disease; Quinpirole; Rats; Rats, Wistar; Receptors, Dopamine D2; Reference Values; Rest; Subthalamic Nucleus; Wakefulness	2002
Behavioral and anatomical effects of long-term L-dihydroxyphenylalanine (L-DOPA) administration in rats with unilateral lesions of the nigrostriatal system. Experimental neurology, 2002, Volume: 177, Issue:1 Topics: Animals; Corpus Striatum; Dyskinesias; Genes, fos; Injections, Intraventricular; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra	2002
[Variance in effects of subthalamic nucleus stimulation]. No to shinkei = Brain and nerve, 2002, Volume: 54, Issue:10 Topics: Aged; Dyskinesias; Electric Stimulation Therapy; Humans; Levodopa; Middle Aged; Parkinson Disease; Subthalamic Nucleus	2002
Dopamine agonists for Parkinson's disease. Lancet (London, England), 2003, Jan-04, Volume: 361, Issue:9351 Topics: Dopamine Agonists; Dyskinesias; Humans; Levodopa; Parkinson Disease	2003
Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2002, Volume: 23 Suppl 2 Topics: Administration, Oral; Aged; Body Weight; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sex Factors	2002
Treatment of advanced Parkinson's disease by subthalamotomy: one-year results. Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:5 Topics: Adult; Aged; Antiparkinson Agents; Dyskinesias; Electrocoagulation; Female; Follow-Up Studies; Humans; Hypokinesia; Levodopa; Magnetic Resonance Imaging; Male; Microelectrodes; Middle Aged; Parkinson Disease; Postoperative Complications; Posture; Severity of Illness Index; Subthalamic Nucleus; Surveys and Questionnaires; Time	2003
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. The European journal of neuroscience, 2003, Volume: 18, Issue:6 Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Benzazepines; Benzoxazines; Brain Chemistry; Cannabinoid Receptor Modulators; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Dyskinesias; Endocannabinoids; Gas Chromatography-Mass Spectrometry; Levodopa; Male; Morpholines; Mouth; Naphthalenes; Oxidopamine; Parkinson Disease; Piperidines; Pyrazoles; Raclopride; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Substantia Nigra; Time Factors	2003
Persistent hemiballism after subthalamotomy: the size of the lesion matters more than the location. Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:10 Topics: Antiparkinson Agents; Corpus Striatum; Dyskinesias; Female; Functional Laterality; Humans; Levodopa; Middle Aged; Neurosurgical Procedures; Parkinsonian Disorders; Postoperative Complications; Thalamus	2003
Levodopa pharmacokinetics and dyskinesias: are there sex-related differences? Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2003, Volume: 24, Issue:3 Topics: Aged; Antiparkinson Agents; Area Under Curve; Benserazide; Case-Control Studies; Dyskinesias; Female; Half-Life; Humans; Levodopa; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Parkinson Disease; Sex Characteristics	2003
Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats. Synapse (New York, N.Y.), 2004, Volume: 51, Issue:2 Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesias; Functional Laterality; Levodopa; Male; Motor Activity; Movement; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Stereotyped Behavior; Subthalamic Nucleus; Time Factors	2004
The effects of chronic L-DOPA therapy on pharmacodynamic parameters in a rat model of motor response fluctuations. Experimental neurology, 2003, Volume: 184, Issue:1 Topics: Animals; Antiparkinson Agents; Apomorphine; Autoradiography; Benzamides; Disease Models, Animal; Dopamine Agonists; Dyskinesias; Female; Forelimb; Immunohistochemistry; Levodopa; Medial Forebrain Bundle; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Presynaptic	2003
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. The Journal of pharmacology and experimental therapeutics, 2004, Volume: 309, Issue:3 Topics: Acetylcholine; Animals; Callithrix; Cells, Cultured; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Drug Interactions; Dyskinesias; Electrophysiology; Extracellular Space; Humans; Hypokinesia; Indoles; Levodopa; Male; Motor Activity; MPTP Poisoning; Neuroprotective Agents; Oxazines; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; Reserpine; Rotation	2004
Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. The Journal of pharmacology and experimental therapeutics, 2004, Volume: 310, Issue:1 Topics: Amantadine; Animals; Anticonvulsants; Antiparkinson Agents; Callithrix; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesias; Female; Levetiracetam; Levodopa; Male; MPTP Poisoning; Piracetam	2004
Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain : a journal of neurology, 2004, Volume: 127, Issue:Pt 5 Topics: Aged; Autoradiography; Brain Chemistry; Case-Control Studies; Dopamine; Dyskinesias; Humans; Image Interpretation, Computer-Assisted; In Situ Hybridization; Levodopa; Parkinson Disease; Receptor, Adenosine A2A	2004
Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy). Neurobiology of disease, 2004, Volume: 15, Issue:3 Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesias; Forelimb; Image Processing, Computer-Assisted; Levodopa; Male; Movement Disorders; Parkinson Disease; Rats; Striatonigral Degeneration	2004
Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease. Neuroreport, 2004, Mar-01, Volume: 15, Issue:3 Topics: Animals; Antiparkinson Agents; Behavior, Animal; Cell Count; Dyskinesias; Immunohistochemistry; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase	2004
Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease. Brain research bulletin, 2004, Aug-30, Volume: 64, Issue:2 Topics: Adenosine; Adenosine A2 Receptor Agonists; Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Drug Therapy, Combination; Dyskinesias; Immunohistochemistry; Levodopa; Male; Oxidopamine; Parkinson Disease; Phenethylamines; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase	2004
A young onset Parkinson's patient: a case study. The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses, 2004, Volume: 36, Issue:5 Topics: Activities of Daily Living; Adult; Age of Onset; Amantadine; Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Dibenzothiazepines; Disease Progression; Dyskinesias; Humans; Levodopa; Male; Motor Skills; Nurse's Role; Parkinson Disease; Patient Advocacy; Patient Education as Topic; Quality of Life; Quetiapine Fumarate; Rhabdomyolysis; Severity of Illness Index; Social Support; Treatment Outcome	2004
Hypertrophy of medial globus pallidus and substantia nigra reticulata in 6-hydroxydopamine-lesioned rats treated with L-DOPA: implication for L-DOPA-induced dyskinesia in Parkinson's disease. Neuropathology : official journal of the Japanese Society of Neuropathology, 2004, Volume: 24, Issue:4 Topics: Animals; Dyskinesias; Globus Pallidus; Hypertrophy; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Substantia Nigra	2004
Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours. The European journal of neuroscience, 2005, Volume: 21, Issue:1 Topics: Adrenergic Agents; Animals; Chlorobenzenes; Corpus Striatum; Cyclobutanes; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesias; Functional Laterality; Immunohistochemistry; Levodopa; Male; Motor Activity; Neurotransmitter Uptake Inhibitors; Oxidopamine; Rats; Rats, Wistar; Rotation; Stereotyped Behavior; Time Factors	2005
Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2005, Volume: 19, Issue:6 Topics: Adaptor Proteins, Signal Transducing; Animals; Behavior, Animal; Brain; Brain Chemistry; Cell Membrane; Corpus Striatum; Discs Large Homolog 1 Protein; Disease Models, Animal; Disks Large Homolog 4 Protein; Dyskinesias; Intracellular Signaling Peptides and Proteins; Levodopa; Male; Membrane Proteins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; RNA, Messenger; Subcellular Fractions; Synapses	2005
Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys. Neuroscience, 2005, Volume: 132, Issue:2 Topics: Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Brain; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesias; Female; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Naloxone; Narcotic Antagonists; Narcotics; Nerve Tissue Proteins; Parkinsonian Disorders; Protein Binding; Receptors, Opioid; Saimiri; Sulfur Isotopes	2005
Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect. Prescrire international, 2005, Volume: 14, Issue:76 Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Catechols; Clinical Trials as Topic; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Dyskinesias; France; Gastrointestinal Diseases; Humans; Levodopa; Parkinson Disease	2005
Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder. Clinical neurology and neurosurgery, 2005, Volume: 107, Issue:4 Topics: Age Factors; Aged; Antiparkinson Agents; Case-Control Studies; Clonazepam; Dyskinesias; Female; GABA Modulators; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; REM Sleep Behavior Disorder; Severity of Illness Index	2005
Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys. Neuropharmacology, 2005, Volume: 49, Issue:2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesias; Female; Levodopa; Macaca fascicularis; Motor Activity; Naltrexone; Narcotic Antagonists; Ovariectomy; Parkinsonian Disorders; Statistics, Nonparametric; Time Factors	2005
The first evaluation of brain shift during functional neurosurgery by deformation field analysis. Journal of neurology, neurosurgery, and psychiatry, 2005, Volume: 76, Issue:8 Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesias; Electrodes, Implanted; Gait; Humans; Imaging, Three-Dimensional; Intraoperative Care; Levodopa; Magnetic Resonance Imaging; Male; Microelectrodes; Movement Disorders; Neurosurgical Procedures; Parkinson Disease; Psychoses, Substance-Induced; Radiosurgery; Subthalamic Nucleus	2005
Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech. Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:11 Topics: Adult; Dysarthria; Dyskinesias; Electric Stimulation Therapy; Functional Laterality; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Severity of Illness Index; Subthalamic Nucleus	2005
Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder. Brain : a journal of neurology, 2005, Volume: 128, Issue:Pt 10 Topics: Adolescent; Alcohol Oxidoreductases; Cerebral Palsy; Child; Child, Preschool; Circadian Rhythm; Cognition Disorders; Developmental Disabilities; Dopamine Agents; Dyskinesias; Female; Genotype; Humans; Levodopa; Male; Motor Activity; Movement Disorders	2005
ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biological psychiatry, 2006, Jan-01, Volume: 59, Issue:1 Topics: Animals; Antiparkinson Agents; Behavior, Animal; Blotting, Western; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dyskinesias; Enkephalins; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Immunohistochemistry; In Situ Hybridization; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Precursors; Proto-Oncogene Proteins c-fos; RNA, Messenger; Statistics, Nonparametric; Time Factors	2006
Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiology of disease, 2006, Volume: 21, Issue:3 Topics: Animals; Brain Tissue Transplantation; Dyskinesias; Female; Fetal Tissue Transplantation; Levodopa; Mesencephalon; Nerve Regeneration; Neurons; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley	2006
Evolution of Parkinson's disease during 4 years of bilateral deep brain stimulation of the subthalamic nucleus. Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:5 Topics: Activities of Daily Living; Adult; Aged; Analysis of Variance; Antiparkinson Agents; Body Weight; Deep Brain Stimulation; Disease Progression; Dyskinesias; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Motor Skills; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome	2006
Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. European journal of neurology, 2005, Volume: 12, Issue:12 Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Depression; Dyskinesias; Europe; Female; Health Care Costs; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life	2005
Dyskinesias induced by subthalamotomy in Parkinson's disease are unresponsive to amantadine. Journal of neurology, neurosurgery, and psychiatry, 2006, Volume: 77, Issue:2 Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Dominance, Cerebral; Dyskinesias; Electric Stimulation Therapy; Female; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Postoperative Complications; Subthalamic Nucleus; Treatment Outcome	2006
Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not L-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat. Neuropharmacology, 2006, Volume: 50, Issue:6 Topics: Analysis of Variance; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesias; Fluorobenzenes; Functional Laterality; Levodopa; Male; Oxidopamine; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Rotarod Performance Test; Serotonin Antagonists; Stereotyped Behavior	2006
Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Annals of neurology, 2006, Volume: 59, Issue:2 Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesias; Female; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Ovariectomy; Severity of Illness Index; Time Factors	2006
Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats. Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:5 Topics: Analysis of Variance; Animals; Antiparkinson Agents; Catechols; Disease Models, Animal; Drug Therapy, Combination; Dyskinesias; Levodopa; Male; Nitriles; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Time Factors	2006
Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats. Synapse (New York, N.Y.), 2006, Jun-01, Volume: 59, Issue:7 Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adenosine; Adrenergic Agents; Animals; Caffeine; Corpus Striatum; Dynorphins; Dyskinesias; Enkephalins; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; RNA, Messenger	2006
Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiology of disease, 2006, Volume: 22, Issue:3 Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesias; Extracellular Fluid; Homovanillic Acid; Levodopa; Male; Membrane Potentials; Microdialysis; Neurons; Oxidopamine; Rats; Rats, Wistar; Substantia Nigra	2006
Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain research bulletin, 2006, Apr-14, Volume: 69, Issue:3 Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesias; Functional Laterality; Haloperidol; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Pyridines; Quinolines; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Rotarod Performance Test; Thiazoles; Time Factors	2006
L-DOPA-induced dyskinesia in adult rats with a unilateral 6-OHDA lesion of dopamine neurons is paralleled by increased c-fos gene expression in the subthalamic nucleus. The European journal of neuroscience, 2006, Volume: 23, Issue:9 Topics: Animals; Autoradiography; Behavior, Animal; Dopamine; Dopamine Agents; Dopamine Uptake Inhibitors; Dyskinesias; Functional Laterality; Gene Expression; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Mazindol; Neurons; Oxidopamine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Substantia Nigra; Subthalamic Nucleus; Time Factors; Tritium	2006
OFF-off rebound dyskinesia in subthalamic nucleus deep brain stimulation of Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:9 Topics: Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Corpus Striatum; Deep Brain Stimulation; Dominance, Cerebral; Drug Therapy, Combination; Dyskinesias; Electrodes, Implanted; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Secondary Prevention; Stereotaxic Techniques; Substance Withdrawal Syndrome; Subthalamic Nucleus	2006
Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias. Clinical chemistry and laboratory medicine, 2006, Volume: 44, Issue:7 Topics: Cross-Sectional Studies; Dyskinesias; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease	2006
Efficacy and safety of simultaneous bilateral pallidotomy in advanced Parkinson's disease. European neurology, 2006, Volume: 56, Issue:2 Topics: Adult; Aged; Antiparkinson Agents; Dyskinesias; Female; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Radiosurgery; Treatment Outcome	2006
Bilateral effects of unilateral subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. European neurology, 2006, Volume: 56, Issue:2 Topics: Activities of Daily Living; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesias; Female; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Subthalamic Nucleus	2006
Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission. The European journal of neuroscience, 2006, Volume: 24, Issue:6 Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Radiation; Drug Interactions; Dyskinesias; Electric Stimulation; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Functional Laterality; Levodopa; Male; Membrane Potentials; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Subthalamic Nucleus; Time Factors	2006
Perceptual factors contribute to akinesia in Parkinson's disease. Experimental brain research, 2007, Volume: 179, Issue:2 Topics: Adult; Aged; Antiparkinson Agents; Dopamine; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Perception; Psychomotor Performance; Reaction Time	2007
Dihydropteridine reductase deficiency: levodopa's long-term effectiveness without dyskinesia. Neurology, 2006, Dec-26, Volume: 67, Issue:12 Topics: 5-Hydroxytryptophan; Adult; Antidepressive Agents, Second-Generation; Dopamine Agents; Drug Combinations; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Longitudinal Studies; Male; Phenylketonurias; Treatment Outcome	2006
Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias. Movement disorders : official journal of the Movement Disorder Society, 2007, Mar-15, Volume: 22, Issue:4 Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Disease Progression; Dopamine; Dyskinesias; Extremities; Levodopa; Male; Mesencephalon; Nerve Degeneration; Parkinson Disease; Prosencephalon; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Substantia Nigra; Tyrosine 3-Monooxygenase	2007
High-frequency stimulation of the subthalamic nucleus potentiates L-DOPA-induced neurochemical changes in the striatum in a rat model of Parkinson's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2007, Feb-28, Volume: 27, Issue:9 Topics: Animals; Biomarkers; Deep Brain Stimulation; Denervation; Disease Models, Animal; Drug Synergism; Dyskinesias; Electron Transport Complex IV; Levodopa; Male; Motor Cortex; Neuropeptides; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Subthalamic Nucleus	2007
Prevalence and treatment strategies of dyskinesia in patients with Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2007, Volume: 114, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Disability Evaluation; Disease Progression; Dyskinesias; Female; Germany; Humans; Interviews as Topic; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Retrospective Studies; Treatment Outcome	2007
The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain research, 2007, Jul-16, Volume: 1158 Topics: Adrenergic Agents; Analysis of Variance; Animals; Behavior, Animal; Biogenic Monoamines; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine Agents; Drug Interactions; Dyskinesias; gamma-Aminobutyric Acid; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine; Serotonin Receptor Agonists; Stereotyped Behavior; Triglycerides	2007
Levodopa-induced ocular dyskinesia in Parkinson's disease. European journal of neurology, 2007, Volume: 14, Issue:10 Topics: Aged; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Ocular Motility Disorders; Parkinson Disease; Prospective Studies	2007
Paradoxical kinesia at war. Movement disorders : official journal of the Movement Disorder Society, 2007, Volume: 22, Issue:16 Topics: Acoustic Stimulation; Aged; Antiparkinson Agents; Anxiety; Cues; Depression; Dyskinesias; Fear; Female; Humans; Israel; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Stress, Psychological; Warfare	2007
Nighttime sleep problems and daytime sleepiness in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2008, Volume: 23, Issue:1 Topics: Adult; Antiparkinson Agents; Demography; Depressive Disorder; Disorders of Excessive Somnolence; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Risk Factors; Severity of Illness Index; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires	2008
Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's disease. Acta neurochirurgica, 2008, Volume: 150, Issue:1 Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesias; Electrodes, Implanted; Female; Gait Disorders, Neurologic; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Posture; Psychoses, Substance-Induced; Retrospective Studies; Subthalamic Nucleus; Tremor	2008
Homozygous SCA 2 mutations changes phenotype and hastens progression. Movement disorders : official journal of the Movement Disorder Society, 2008, Apr-15, Volume: 23, Issue:5 Topics: Antiparkinson Agents; Ataxins; Dementia; Disease Progression; Dyskinesias; Female; Follow-Up Studies; Homozygote; Humans; Levodopa; Male; Mutation; Nerve Tissue Proteins; Ocular Motility Disorders; Parkinsonian Disorders; Phenotype; Psychotic Disorders; Spinocerebellar Degenerations	2008
The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Movement disorders : official journal of the Movement Disorder Society, 2008, Apr-30, Volume: 23, Issue:6 Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Australia; Dementia; Dyskinesias; Female; Follow-Up Studies; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors	2008
[Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure]. Medecine sciences : M/S, 2008, Volume: 24, Issue:4 Topics: Corpus Striatum; Drug Administration Schedule; Dyskinesias; Humans; Levodopa; Parkinson Disease	2008
The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2008, Apr-23, Volume: 28, Issue:17 Topics: Animals; Dyskinesias; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Levodopa; Lovastatin; Male; Parkinson Disease, Secondary; Rats; Rats, Wistar; Severity of Illness Index	2008
The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14, Issue:5 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Antagonists; Animals; Antiparkinson Agents; Brain; Callithrix; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesias; Female; Idazoxan; Levodopa; Male; Receptors, Adrenergic, alpha-2; Time Factors; Yohimbine	1999
Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology, 1999, Sep-22, Volume: 53, Issue:5 Topics: Adrenergic alpha-Antagonists; Aged; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Levodopa; Male; Mianserin; Middle Aged; Mirtazapine; Parkinson Disease	1999
Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology, 1999, Oct-22, Volume: 53, Issue:7 Topics: Adult; Aged; Alleles; Antiparkinson Agents; Case-Control Studies; Dyskinesia, Drug-Induced; Dyskinesias; Female; Gene Frequency; Genetic Predisposition to Disease; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Receptors, Dopamine D2; Tandem Repeat Sequences	1999
Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. Annals of neurology, 1999, Volume: 46, Issue:5 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Dyskinesias; Electrophysiology; Eye Movements; Globus Pallidus; Levodopa; Macaca mulatta; Motor Activity; Neurons; Parkinsonian Disorders	1999
Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease. Pharmacotherapy, 1999, Volume: 19, Issue:11 Pt 2 Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Disease Progression; Dopamine Agonists; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Odds Ratio; Parkinson Disease	1999
Successful orchestration of antiparkinsonian pharmacotherapy. Pharmacotherapy, 1999, Volume: 19, Issue:11 Pt 2 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Comorbidity; Disease Progression; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pharmacists	1999
Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiology of disease, 1999, Volume: 6, Issue:6 Topics: Animals; Antisense Elements (Genetics); Bacterial Proteins; Biomarkers; Cell Count; Disease Models, Animal; Dyskinesias; Enkephalins; Female; Levodopa; Neostriatum; Nerve Degeneration; Neurons; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Transcription Factors; Ventral Tegmental Area	1999
[Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)]. Neurologia (Barcelona, Spain), 2001, Volume: 16, Issue:2 Topics: Aged; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine; Drug Therapy, Combination; Dyskinesias; Humans; Levodopa; Nitriles; Parkinson Disease	2001
A case of spontaneous arm levitation in progressive supranuclear palsy. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2000, Volume: 21, Issue:6 Topics: Aged; Arm; Dopamine Agents; Dyskinesias; Humans; Levodopa; Male; Supranuclear Palsy, Progressive; Treatment Failure	2000
Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Experimental neurology, 2001, Volume: 171, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Drug Therapy, Combination; Dyskinesias; Female; Hypokinesia; Levodopa; Male; Morphinans; Motor Activity; Naltrexone; Narcotic Antagonists; Parkinsonian Disorders; Posture; Receptors, Opioid, delta; Receptors, Opioid, mu	2001
Assessment of motor behavior using a video system and a clinical rating scale in parkinsonian monkeys lesioned by MPTP. Journal of neuroscience methods, 2001, Oct-15, Volume: 111, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Chronic Disease; Disability Evaluation; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Dyskinesias; Female; Image Processing, Computer-Assisted; Levodopa; Macaca mulatta; Motor Activity; Parkinsonian Disorders; Video Recording	2001